<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OL</journal-id>
<journal-title-group>
<journal-title>Oncology Letters</journal-title>
</journal-title-group>
<issn pub-type="ppub">1792-1074</issn>
<issn pub-type="epub">1792-1082</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/ol.2021.13064</article-id>
<article-id pub-id-type="publisher-id">OL-0-0-13064</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Analysis of expression profiles and prognostic value of COP9 signalosome subunits for patients with head and neck squamous cell carcinoma</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Hao</given-names></name>
<xref rid="af1-ol-0-0-13064" ref-type="aff"/>
<xref rid="fn1-ol-0-0-13064" ref-type="author-notes">&#x002A;</xref></contrib>
<contrib contrib-type="author"><name><surname>Sun</surname><given-names>Wei</given-names></name>
<xref rid="af1-ol-0-0-13064" ref-type="aff"/>
<xref rid="fn1-ol-0-0-13064" ref-type="author-notes">&#x002A;</xref></contrib>
<contrib contrib-type="author"><name><surname>Zou</surname><given-names>Jiaruan</given-names></name>
<xref rid="af1-ol-0-0-13064" ref-type="aff"/>
<xref rid="c1-ol-0-0-13064" ref-type="corresp"/></contrib>
</contrib-group>
<aff id="af1-ol-0-0-13064">Department of Oral and Maxillofacial Surgery, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430000, P.R. China</aff>
<author-notes>
<corresp id="c1-ol-0-0-13064"><italic>Correspondence to</italic>: Dr Jiaruan Zou, Department of Oral and Maxillofacial Surgery, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, 14 Kusaoshu Road, Wuhan, Hubei 430000, P.R. China, E-mail: <email>z88688521@126.com</email></corresp>
<fn id="fn1-ol-0-0-13064"><label>&#x002A;</label><p>Contributed equally</p></fn></author-notes>
<pub-date pub-type="ppub">
<month>11</month>
<year>2021</year></pub-date>
<pub-date pub-type="epub">
<day>23</day>
<month>09</month>
<year>2021</year></pub-date>
<volume>22</volume>
<issue>5</issue>
<elocation-id>803</elocation-id>
<history>
<date date-type="received"><day>14</day><month>05</month><year>2021</year></date>
<date date-type="accepted"><day>14</day><month>07</month><year>2021</year></date>
</history>
<permissions>
<copyright-statement>Copyright: &#x00A9; Zhou et al.</copyright-statement>
<copyright-year>2021</copyright-year>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license>
</permissions>
<abstract>
<p>Head and neck squamous cell carcinoma (HNSCC) has been associated with poor prognosis, due to its strong invasive ability and resistance to chemotherapy. Thus, there is an urgent requirement to identify effective biomarkers for the early diagnosis and prognostic evaluation of HNSCC. COP9 signalosome (COPS) regulates numerous cancer-associated biological processes in various malignancies. The aim of the present study was to investigate the association between COPS and HNSCC. The mRNA expression profiles of COPS in HNSCC were analyzed using UALCAN, Oncomine and UCSC Xena databases. The association between overall survival time in patients with HNSCC and the COPS genes was investigated using the Kaplan-Meier plotter database. The CERES score was obtained and evaluated to determine the importance of the COPS genes for survival of the HNSCC cell lines. Functional analysis for Gene Ontology and Gene Set Enrichment Analysis (GSEA) was performed using The Database for Annotation, Visualization and Integrated Discovery and GSEA software, respectively. After knocking down COPS5 and COPS6, cell Counting Kit-8 and wound healing assays were used to detect cell growth and migration of the CAL27 and SCC25 cell lines, respectively. Among the 10 COPS genes examined, most COPS subunits were upregulated in HNSCC samples compared with that in normal tissues, except for COPS9. Increased mRNA expression level of COPS5, COPS6, COPS7B, COPS8 and COPS9 was associated with TNM stage in patients with HNSCC. High mRNA expression level of COPS2, COPS5, COPS6, COPS7A, COPS7B, COPS8 and COPS9 had prognostic significance of patients with HNSCC. Knockdown of COPS5 and COPS6 inhibited cell growth and migration of the CAL27 and SCC25 cell lines. The results from the present study suggested that COPS subunits could be potential biomarkers in patients with HNSCC. COPS5 and COPS6 were important for cell survival and migration of the HNSCC cells.</p>
</abstract>
<kwd-group>
<kwd>COPS9</kwd>
<kwd>head and neck squamous cell carcinoma</kwd>
<kwd>prognostic factor</kwd>
<kwd>biomarker</kwd>
<kwd>cell survival</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>Youth Science Support Project of the Central Hospital of Wuhan</funding-source>
<award-id>201807632</award-id>
</award-group>
<funding-statement>This research was supported by a grant from the Youth Science Support Project of the Central Hospital of Wuhan (grant no. 201807632).</funding-statement>
</funding-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Head and neck squamous cell carcinoma (HNSCC) is the major pathological subtype of head and neck cancer (<xref rid="b1-ol-0-0-13064" ref-type="bibr">1</xref>). Every year, &#x003E;600,000 new patients are diagnosed worldwide, and 300,000 individuals succumb to the disease (<xref rid="b2-ol-0-0-13064" ref-type="bibr">2</xref>). The methods for the diagnosis and treatment of HNSCC have developed rapidly; however, the prognosis of patients with HNSCC remains poor (<xref rid="b3-ol-0-0-13064" ref-type="bibr">3</xref>). Identifying biomarkers in body fluids is considered important for the earlier diagnosis of HNSCC (<xref rid="b4-ol-0-0-13064" ref-type="bibr">4</xref>). For example, salivary IL-8 and &#x2212;6 and tumor necrosis factor (TNF) have been beneficial for the diagnosis of oral squamous cell carcinoma (<xref rid="b5-ol-0-0-13064" ref-type="bibr">5</xref>). However, the conclusions from different studies are still incomplete (<xref rid="b4-ol-0-0-13064" ref-type="bibr">4</xref>). Therefore, identifying novel biomarkers for HNSCC detection is important for definitive and effective diagnosis leading to timely prevention, precise treatment and alleviating the recurrence of HNSCC.</p>
<p>The COP9 signalosome (COPS) is an evolutionarily conserved complex of 8 protein subunits (COPS1-8) (<xref rid="b6-ol-0-0-13064" ref-type="bibr">6</xref>). The known biochemical activity of the COPS is to serve as the deneddylase to remove NEDD8 from a neddylated cullin, in the cullin-RING-E3 ligases (CRLs) via deneddylation, which is further enhanced by linking with the 9th subunit, COPS9 (<xref rid="b7-ol-0-0-13064" ref-type="bibr">7</xref>,<xref rid="b8-ol-0-0-13064" ref-type="bibr">8</xref>). COPS regulates numerous cellular and biological processes, such as embryonic development, cell cycle, DNA damage repair, checkpoint repair control, signal transduction, circadian rhythm, T-cell development and autophagy (<xref rid="b9-ol-0-0-13064" ref-type="bibr">9</xref>). COPS accomplishes these various functions by controlling CRLs, the most prominent class of E3-enzymes, which promote ubiquitination of a variety of regulatory proteins subsequently targeted for proteasomal degradation (<xref rid="b10-ol-0-0-13064" ref-type="bibr">10</xref>). In addition, the catalytic center of the COPS is harbored in COPS5 (<xref rid="b11-ol-0-0-13064" ref-type="bibr">11</xref>).</p>
<p>The COPS subunits, which form the lid complex (19S) of the 26S proteasome, are paralogous (<xref rid="b12-ol-0-0-13064" ref-type="bibr">12</xref>). The 19S complex can specifically recognize ubiquitinated substrates and induce their degradation (<xref rid="b13-ol-0-0-13064" ref-type="bibr">13</xref>). Given the characteristics of the COPS, numerous tumor-associated genes have been identified, including hypoxia inducible factor 1 (HIF1), p27, runt related transcription factor 3 and p53 (<xref rid="b14-ol-0-0-13064" ref-type="bibr">14</xref>&#x2013;<xref rid="b17-ol-0-0-13064" ref-type="bibr">17</xref>). The oncoprotein Jab1/COPS5 is associated with the pathogenesis of nasopharyngeal carcinoma (<xref rid="b11-ol-0-0-13064" ref-type="bibr">11</xref>). COPS5 is overexpressed in thyroid carcinoma cell lines and associated with low expression of p27 (<xref rid="b18-ol-0-0-13064" ref-type="bibr">18</xref>). Epidermal growth factor receptor-extracellular regulated MAP kinase signaling pathway may upregulate COPS6, which inhibited programmed cell death ligand-1 (PD-L1) degradation and subsequently maintains PD-L1 stability in glioblastoma (<xref rid="b19-ol-0-0-13064" ref-type="bibr">19</xref>,<xref rid="b20-ol-0-0-13064" ref-type="bibr">20</xref>). In ultraviolet-irradiated cells, COPS1 is associated with both the DNA repair process and cell apoptosis in HeLa cells (<xref rid="b21-ol-0-0-13064" ref-type="bibr">21</xref>). COPS3 is associated with cell growth arrest mediated by myeloid leukemia factor 1 and impairs the activation of p53, which promotes cell proliferation and blocks constitutively photomorphogenic 1-mediated p53 degradation (<xref rid="b22-ol-0-0-13064" ref-type="bibr">22</xref>). COPS2 overexpression upregulates the production of vascular endothelial growth factor and promotes the stability of cyclin A (<xref rid="b23-ol-0-0-13064" ref-type="bibr">23</xref>). COPS4 deficiency facilitates the downregulation of S-phase kinase associated protein 2, which is associated with the degradation of p27 (<xref rid="b24-ol-0-0-13064" ref-type="bibr">24</xref>).</p>
<p>Compared with normal tissues, COPS5 and COPS6 have both been found to be upregulated &#x003E;40&#x0025; at the mRNA level in several types of human cancer tissues, including myeloma, lung cancer, colon adenocarcinoma, breast cancer, glioblastoma and leukemia (<xref rid="b25-ol-0-0-13064" ref-type="bibr">25</xref>). Using a proteome microarray method, Yang <italic>et al</italic> (<xref rid="b26-ol-0-0-13064" ref-type="bibr">26</xref>) found that COPS2 expression was significantly higher in the serum of patients with gastric cancer compared with that in healthy individuals, and the mRNA expression level of COPS2 was associated with poor prognosis. The amplification of COPS3 was found in 31&#x0025; of patients with osteosarcoma and was significantly associated with the size of the tumor (<xref rid="b27-ol-0-0-13064" ref-type="bibr">27</xref>). In addition, COPS3 is upregulated in clear cell renal cell carcinoma tissues and cell lines and patients with high expression of COPS3 have lower overall survival (OS) rate (<xref rid="b28-ol-0-0-13064" ref-type="bibr">28</xref>). The mRNA level of COPS8 is upregulated and predicts a poor clinical outcome in patients with cutaneous melanoma (<xref rid="b29-ol-0-0-13064" ref-type="bibr">29</xref>). However, to the best of our best knowledge, the association between the COPS subunits and HNSCC remains unknown.</p>
<p>Therefore, the present study aimed to investigate the association between the expression profiles of the COPS subunits and HNSCC. It was found that the COPS subunits were highly expressed in the HNSCC samples compared with that in normal tissues, except for COPS9. High mRNA expression levels of COPS2, COPS5, COPS6, COPS7A, COPS7B, COPS8 and COPS9 had prognostic significance in patients with HNSCC. COPS5 and COPS6 could be important for the process of HNSCC.</p>
</sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec>
<title/>
<sec>
<title>Cell culture</title>
<p>The human tongue squamous cell carcinoma cell lines, CAL27 and SCC25, were kindly provided by Professor Liang Jiang (Tongji Hospital, Hubei, China). The CAL27 and SCC25 cell lines were cultured in complete DMEM (Hyclone; Cytiva) containing 10&#x0025; FBS (Lonza Group, Ltd.) with 100 U/ml streptomycin and penicillin (Thermo Fisher Scientific, Inc.). Both the cell lines were cultured at 37&#x00B0;C in a humidified incubator with 5&#x0025; CO<sub>2</sub>. The CAL27 and SCC25 cell lines were harvested using 0.25&#x0025; trypsin-EDTA (Thermo Fisher Scientific, Inc.) when it reached 80&#x0025; confluence.</p>
</sec>
<sec>
<title>Cell transfection</title>
<p>The CAL27 and SCC25 cell lines were transfected with small interfering (si)RNA targeting COPS5 (5&#x2032;-UUCUCAUACUGUCUUUCAGGUCUGAAAGACAGUAUGAGAAAA-3&#x2032;) or COPS6 (5&#x2032;-UUGAUUAUAUCAAUGACAGACCUGUCAUUGAUAUAAUCAAUG-3&#x2032;) or a non-specific control (50 nM) using Lipofectamine<sup>&#x00AE;</sup> 2000 transfection reagent (Thermo Fisher Scientific, Inc.) according to the manufacturer&#x0027;s instructions. After cell transfection with siRNA for 4 h at 37&#x00B0;C, the medium was replaced. After 48 h transfection, cells were used for western blot analysis and wound healing assay. After 24 or 48 h transfected, cell viability was tested.</p>
</sec>
<sec>
<title>Western blot analysis</title>
<p>Proteins from CAL27 and SCC25 cells were extracted using RIPA lysate (Beyotime Biotechnology, China) containing 1&#x00D7; protease inhibitor (Thermo Fisher Scientific, USA) at 80&#x2013;90&#x0025; density. The protein concentration was determined by a BCA method (Beyotime Institute of Biotechnology) according to the manufacturer&#x0027;s instructions. Total protein (20 &#x00B5;g) was separated using 10&#x0025; SDS-PAGE and transferred to 0.2-&#x00B5;m PVDF membranes (Bio-Rad Laboratories) at 100 V for 80 min. After being blocked with TBS containing 0.1&#x0025; Tween-20 (TBST) and 5&#x0025; skimmed milk for 1 h at room temperature, the PVDF membrane was incubated with the primary antibody overnight at 4&#x00B0;C. The next day, after being washed 3 times with TBST, the membrane was incubated with the goat anti-mouse secondary antibody (cat. no. SA00001-1; 1:10,000; ProteinTech Group, Inc.) for 1 h at room temperature, then the bands were visualized using an ECL developing system (Beyotime Institute of Biotechnology). The following antibodies were used: Mouse monoclonal anti-COPS5 (cat. no. sc-13157; 1:200; Santa Cruz Biotechnology, Inc.), mouse monoclonal anti-COPS6 (cat. no. sc-137153; 1:200; Santa Cruz biotechnology, Inc.) and mouse monoclonal anti-GAPDH (cat no. ab8245; 1:10,000; Abcam).</p>
</sec>
<sec>
<title>Cell viability</title>
<p>Following transfection with the siRNA, the cell lines (1&#x00D7;10<sup>4</sup>) were collected and seeded in 96-well plates. The cells were then incubated with complete medium for 24 or 48 h and 10 &#x00B5;g Cell Counting Kit-8 reagent (MedChemExpress) was added into each well. The cells were incubated in 37&#x00B0;C for 30 min, then the samples were measured at 450 nm.</p>
</sec>
<sec>
<title>Wound healing assay</title>
<p>The CAL27 and SCC25 (1&#x00D7;10<sup>5</sup>) cell lines were seeded in 12-well plate. Then, cells were transfected with siRNA or control. After the cells were cultured to 80&#x2013;90&#x0025; confluence with complete DMEM medium with 10&#x0025; FBS, the cells were scratched slightly, then washed with PBS three times. Subsequently, the cells were incubated with DMEM without FBS for 48 h and images of the cells were captured with normal light microscope (BX51; Olympus Corporation). The wound was quantified by ImageJ with the Wound Healing Coherency Tool (version 1.8.0; national Institute of Health).</p>
</sec>
<sec>
<title>Datasets and samples</title>
<p>The RNA expression profile and clinical data sets were obtained from The Cancer Genome Atlas (TCGA) database (<uri xlink:href="https://gdc.cancer.gov">https://gdc.cancer.gov</uri>), which included 520 patients with HNSCC and 44 adjacent normal samples. After excluding the samples with survival times &#x003C;30 days, missing clinical information and data integration, a total of 490 samples were used to perform the prognostic analysis.</p>
</sec>
<sec>
<title>mRNA profiles of the COPS subunits</title>
<p>The ONCOMINE database (<uri xlink:href="https://www.oncomine.org">www.oncomine.org</uri>) is the world&#x0027;s largest oncogene chip database and integrated data mining platform. A total of 11 datasets (Pyeon Multi-cancer, Sengupta Head-Neck, Toruner Head-Neck, Schlingemann Head-Neck, Cromer Head-Neck, Ginos Head-Neck, Giordano Thyroid, Peng Head-Neck, Ye Head-Neck, Vasko Thyroid and He Thyroid) were included in the analysis (<xref rid="b30-ol-0-0-13064" ref-type="bibr">30</xref>&#x2013;<xref rid="b35-ol-0-0-13064" ref-type="bibr">35</xref>). The mRNA expression level of the COPS subunits in the clinical HNSCC specimens were compared with that in adjacent normal controls, using an unpaired Student&#x0027;s t-test. The fold change and P-value thresholds were defined as 1.5 and 0.01, respectively. TCGA gene expression data of the COPS subunits was determined using UALCAN (<uri xlink:href="https://ualcan.path.uab.edu">http://ualcan.path.uab.edu</uri>) using the &#x2018;TCGA-HNSC&#x2019; module, which provides systematical and personalized analysis of TCGA database. University of California Santa Cruz (UCSC) Xena (<uri xlink:href="https://xenabrowser.net/">http://xenabrowser.net/</uri>) is a comprehensive web analysis tool which provides customized analysis methods of TCGA data. To evaluate different mRNA expression levels of the COPS subunits and the TMN stages in primary HNSCC (n=765), UCSC Xena was used with a one-way ANOVA analysis followed by Bonferroni&#x0027;s post hoc test.</p>
</sec>
<sec>
<title>Prognosis evaluation of the COPS subunits in HNSCC</title>
<p>The Kaplan-Meier plotter (<uri xlink:href="https://www.kmplot.com">www.kmplot.com</uri>) includes the 21 types of TCGA datasets to evaluate the prognostic value of 54,000 genes in different types of cancer. The association between mRNA expression levels of all the COPS subunits and prognosis in patients with HNSCC was analyzed using the Kaplan-Meier plotter. All the patients were divided into two groups automatically using the best outcome setting. The hazard ratio (HR) with 95&#x0025; confidence intervals (CI) and log-rank were obtained to evaluate the prognostic difference in patients with HNSCC.</p>
</sec>
<sec>
<title>Protein-protein interaction (PPI) network of the COPS subunits</title>
<p>To construct the PPI network of the COPS subunits, Search Tool for the Retrieval of Interacting Genes/Proteins (STRING; <uri xlink:href="https://string-db.org/">http://string-db.org/</uri>), which includes both certified and predicated links, was used. In total, 10 COPS subunits (COPS1-6, 7A and B, 8 and 9) and <italic>Homo sapiens</italic> (organism) were selected for the analysis. Extra 50 associated nodes were included in the analysis.</p>
</sec>
<sec>
<title>Gene ontology (GO) enrichment analysis</title>
<p>GO enrichment analysis was performed using The Database for Annotation, Visualization and Integrated Discovery (DAVID; <uri xlink:href="https://david.ncifcrf.gov/">http://david.ncifcrf.gov/</uri>). The catalogues of GO analysis were selected as biological process (BP), cellular components (CC), molecular function (MF) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was also performed. All associated genes (<xref rid="b36-ol-0-0-13064" ref-type="bibr">36</xref>) were included in the analysis. P&#x003C;0.05 was considered as significant. The top 12 affected pathways were included using R version 4.1.0. (R Development Core Team).</p>
</sec>
<sec>
<title>Cell survival analysis</title>
<p>To evaluate the importance of the COPS subunits in survival of the HNSCC cell lines, Project Achilles with CERES dependence scores was used. By accurately removing the expression of the corresponding gene with CRISPR-Cas9 system, Project Achilles systematically investigates and identifies the numbers of genes which are essential for survival of the cancer cell lines. The original data was downloaded from the Depmap portal (<uri xlink:href="https://depmap.org/portal">https://depmap.org/portal</uri>) (<xref rid="b37-ol-0-0-13064" ref-type="bibr">37</xref>). The inclusive criteria were as follow: i) The primary disease was head and neck cancer and ii) the pathological subtype was squamous cell carcinoma. A total of 21 cell lines were included in the analysis.</p>
</sec>
<sec>
<title>Gene set enrichment analysis (GSEA) of COPS subunits</title>
<p>GSEA (<uri xlink:href="https://www.broad.mit.edu/gsea">http://www.broad.mit.edu/gsea</uri>), with the annotated Hallmark effector gene sets, was performed according to the mRNA expression level of the COPS subunits in TCGA-HNSC dataset. The cut-off value of grouping was defined as 50&#x0025;. The false discovery rate q-value &#x003C;0.25 and P&#x003C;0.05 was considered to indicate a significant difference (<xref rid="b38-ol-0-0-13064" ref-type="bibr">38</xref>). The visual results were performed using R version 4.1.0.</p>
</sec>
<sec>
<title>Protein expression of the COPS subunits</title>
<p>The protein expression of COPS subunits was evaluated using immunohistochemistry (IHC) data downloaded from the Human Protein Atlas (HPA) database (<uri xlink:href="https://www.proteinatlas.org/">https://www.proteinatlas.org/</uri>). The following primary antibodies against CCT5 and CCT6 were used CAB004242 and HPA044315.</p>
</sec>
<sec>
<title>Statistical analysis</title>
<p>The HR with log-rank test was used for survival analysis. Spearman&#x0027;s rank correlation test was used to evaluate the correlation of gene expression in tumor tissues compared with normal tissues, and the strength of the association was determined using the absolute values. One-way ANOVA followed by Bonferroni post hoc test was used to evaluate the difference in &#x003E;2 groups. P&#x003C;0.05 was considered to indicate a statistically significant difference.</p>
</sec>
</sec>
</sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title/>
<sec>
<title>mRNA expression profiles of the COPS subunits in HNSCC</title>
<p>A total 10 COPS subunits (COPS1-9) have been identified in human cells (<xref rid="b39-ol-0-0-13064" ref-type="bibr">39</xref>,<xref rid="b40-ol-0-0-13064" ref-type="bibr">40</xref>). To evaluate the mRNA expression levels of the COPS subunits in HNSCC, TCGA dataset (TCGA-HNSC) was used within the UALCAN database. As shown in <xref rid="f1-ol-0-0-13064" ref-type="fig">Fig. 1</xref>, the expression of COPS1-8, but not COPS9, was found to be upregulated in HNSCC tissues compared with that in normal tissues.</p>
<p>To further verify the results, the ONCOMINE database was used to compare the transcriptional levels of the COPS subunits in all types of cancer with the corresponding normal tissue (<xref rid="f2-ol-0-0-13064" ref-type="fig">Fig. 2</xref>). The red color and number indicated the number of datasets with a statistically significant increase (P&#x003C;0.01; fold change, 1.5) in mRNA expression levels in different types of cancers, while the blue color indicated a decrease in mRNA expression of the COPS subunits. There was a total of 11 HNSCC datasets in the ONCOMINE database. The overexpression status of COPS subunits in different parts of HNSCC are presented in <xref rid="tI-ol-0-0-13064" ref-type="table">Table I</xref>. In detail, one dataset indicated COPS1 was upregulated in floor of the mouth carcinoma, and COPS3 was increased in carcinoma from oropharyngeal, oral cavity, floor of the mouth and tongue (Pyeon Multi-cancer) (<xref rid="b30-ol-0-0-13064" ref-type="bibr">30</xref>). The expression of COPS2 was found increased in both NPC (Sengupta Head-Neck) (<xref rid="b31-ol-0-0-13064" ref-type="bibr">31</xref>) and floor of the mouth carcinoma (Pyeon Multi-cancer) (<xref rid="b30-ol-0-0-13064" ref-type="bibr">30</xref>). COPS5 (Pyeon Multi-cancer, Sengupta Head-Neck and Toruner Head-Neck Statistics) (<xref rid="b30-ol-0-0-13064" ref-type="bibr">30</xref>,<xref rid="b31-ol-0-0-13064" ref-type="bibr">31</xref>,<xref rid="b34-ol-0-0-13064" ref-type="bibr">34</xref>) and COPS6 (Pyeon Multi-cancer) (<xref rid="b30-ol-0-0-13064" ref-type="bibr">30</xref>) were upregulated in various sites of HNSCC. In addition, COPS8 was found highly expressed in HNSCC tissues in five datasets (Pyeon Multi-cancer, Sengupta Head-Neck, Schlingemann Head-Neck, Cromer Head-Neck and Ginos Head-Neck) (<xref rid="b30-ol-0-0-13064" ref-type="bibr">30</xref>&#x2013;<xref rid="b33-ol-0-0-13064" ref-type="bibr">33</xref>,<xref rid="b35-ol-0-0-13064" ref-type="bibr">35</xref>). There was no significant difference in the expression of COPS7A, COPS7B and COPS9 between HNSCC and normal tissues in the ONCOMINE database.</p>
</sec>
<sec>
<title>mRNA expression levels of the COPS subunits are associated with TNM stage in patients with HNSCC</title>
<p>As most of the COPS subunits were found to be upregulated in HNSCC tissues, the association between the mRNA expression level of the COPS subunits and TNM stage was investigated. The UCSC Xena web tool was used for the analysis. As shown in <xref rid="f3-ol-0-0-13064" ref-type="fig">Fig. 3A</xref>, the mRNA expression levels of COPS5 and COPS6 were significantly increased with increasing tumor size. With respect to lymph node metastasis, an increase in the expression level of COPS5, COPS6, COPS7B and COPS9 were found in patients with HNSCC and N stage (<xref rid="f3-ol-0-0-13064" ref-type="fig">Fig. 3B</xref>). In addition, increased expression of COPS5, COPS6, COPS8 and COPS9 was associated with distant metastasis of HNSCC (<xref rid="f3-ol-0-0-13064" ref-type="fig">Fig. 3C</xref>).</p>
</sec>
<sec>
<title>Prognostic values of the COPS subunits in patients with HNSCC</title>
<p>The Kaplan-Meier plotter database and TCGA-HNSC dataset was used to investigate whether the COPS subunits were associated with the prognosis of HNSCC. High mRNA expression level of COPS2 (HR, 1.44; CI, 1.09&#x2013;1.9; P=0.0091; <xref rid="f4-ol-0-0-13064" ref-type="fig">Fig. 4B</xref>), COPS5 (HR, 1.32; CI, 1.01&#x2013;1.73; P=0.042; <xref rid="f4-ol-0-0-13064" ref-type="fig">Fig. 4E</xref>), COPS6 (HR, 1.4; CI, 1.06&#x2013;1.84; P=0.019; <xref rid="f4-ol-0-0-13064" ref-type="fig">Fig. 4F</xref>), COPS7A (HR, 1.56 (1.19&#x2013;2.05); P=0.0011; <xref rid="f4-ol-0-0-13064" ref-type="fig">Fig. 4G</xref>), COPS8 (HR, 1.6; CI, 1.16&#x2013;2.19; P=0.0035; <xref rid="f4-ol-0-0-13064" ref-type="fig">Fig. 4I</xref>) and COPS9 (HR, 1.33; CI, 1.02&#x2013;1.74; P=0.035; <xref rid="f4-ol-0-0-13064" ref-type="fig">Fig. 4J</xref>) was associated with poor prognosis in patients with HNSCC. However, high expression of COPS7B (HR, 0.75 (0.57&#x2013;0.98); P=0.038; <xref rid="f4-ol-0-0-13064" ref-type="fig">Fig. 4H</xref>) was associated with improved outcome in patients with HNSCC.</p>
</sec>
<sec>
<title>PPI network construction and GO analysis of the COPS subunits</title>
<p>To predict the functions of the COPS subunits in humans, a PPI network was constructed with the 50 most relevant genes using STRING. The analysis included 60 nodes and 946 edges (<xref rid="f5-ol-0-0-13064" ref-type="fig">Fig. 5</xref>). The PPI enrichment value was P&#x003C;1.0&#x00D7;10<sup>&#x2212;16</sup>.</p>
<p>Then, the biological functions and pathways of the associated genes with the COPS subunits were analyzed using GO and KEGG analysis, respectively. The top 12 GO terms and KEGG pathways are shown in <xref rid="f6-ol-0-0-13064" ref-type="fig">Fig. 6</xref>. With respect to BP, &#x2018;protein ubiquitination involved in ubiquitin-dependent protein catabolic process&#x2019;, &#x2018;Fc-epsilon receptor signaling pathway&#x2019;, &#x2018;nucleotide-excision repair, preincision complex stabilization&#x2019; and &#x2018;G<sub>1</sub>/S transition of mitotic cell cycle&#x2019; were significantly associated with the COPS subunits (<xref rid="f6-ol-0-0-13064" ref-type="fig">Fig. 6A</xref>; <xref rid="SD1-ol-0-0-13064" ref-type="supplementary-material">Table SI</xref>). For CC, the genes were associated with &#x2018;Cul3-RING ubiquitin ligase complex&#x2019;, &#x2018;nucleoplasm&#x2019; and &#x2018;cytosol&#x2019; (<xref rid="f6-ol-0-0-13064" ref-type="fig">Fig. 6B</xref>; <xref rid="SD1-ol-0-0-13064" ref-type="supplementary-material">Table SII</xref>). The genes associated with MF were &#x2018;ubiquitin-protein transferase activity&#x2019;, &#x2018;MAP kinase activity&#x2019;, &#x2018;NEDD8 transferase activity&#x2019; and &#x2018;JUN kinase activity&#x2019;, which were cancer relative pathways (<xref rid="f6-ol-0-0-13064" ref-type="fig">Fig. 6C</xref>; <xref rid="SD1-ol-0-0-13064" ref-type="supplementary-material">Table SIII</xref>). KEGG pathway analysis identifies the functions of the COPS subunits and the pathways they are involved in. The top 12 pathways are shown in <xref rid="f6-ol-0-0-13064" ref-type="fig">Fig. 6D</xref> and <xref rid="SD1-ol-0-0-13064" ref-type="supplementary-material">Table SIV</xref>. Among these pathways, &#x2018;ubiquitin mediated proteolysis&#x2019;, &#x2018;renal cell carcinoma&#x2019;, &#x2018;pathways in cancer&#x2019;, &#x2018;colorectal cancer&#x2019;, &#x2018;Toll-like receptor signaling pathway&#x2019; and &#x2018;TNF signaling pathway&#x2019; were observed.</p>
</sec>
<sec>
<title>GSEA analysis of COPS5, COPS6 and COPS8</title>
<p>In HNSCC, COPS5, COPS6 and COPS8 are essential for cell growth and, as aforementioned, associated with tumor TNM stages and prognosis. Hence, it is important to evaluate the functions of these three genes and GSEA was performed to evaluate Hallmark annotation. As shown in <xref rid="f7-ol-0-0-13064" ref-type="fig">Fig. 7A</xref> and <xref rid="SD1-ol-0-0-13064" ref-type="supplementary-material">Table SV</xref>, high expression of COPS5 was associated with tumorigenesis-associated pathway including &#x2018;DNA repair&#x2019;, &#x2018;unfolded protein response&#x2019;, &#x2018;MTORC1 signaling&#x2019;, &#x2018;glycolysis&#x2019; and &#x2018;PI3K AKT mTOR signaling&#x2019;. In addition to these pathways, increased COPS6 was also associated with &#x2018;oxidative phosphorylation&#x2019; and &#x2018;p53 pathway&#x2019; (<xref rid="f7-ol-0-0-13064" ref-type="fig">Fig. 7B</xref> and <xref rid="SD1-ol-0-0-13064" ref-type="supplementary-material">Table SVI</xref>). Similarly, COPS8 was additionally associated with &#x2018;apoptosis&#x2019; (<xref rid="f7-ol-0-0-13064" ref-type="fig">Fig. 7C</xref> and <xref rid="SD1-ol-0-0-13064" ref-type="supplementary-material">Table SVII</xref>).</p>
</sec>
<sec>
<title>IHC analysis of the protein expression level of the COPS subunits in HNSCC</title>
<p>The protein expression level of the COPS subunits in HNSCC was investigated using the HPA database. Consistent with the mRNA expression level, COPS2 (<xref rid="SD1-ol-0-0-13064" ref-type="supplementary-material">Fig. S1A</xref>), COPS3 (<xref rid="SD1-ol-0-0-13064" ref-type="supplementary-material">Fig. S1B</xref>), COPS4 (<xref rid="SD1-ol-0-0-13064" ref-type="supplementary-material">Fig. S1C</xref>), COPS5 (<xref rid="f8-ol-0-0-13064" ref-type="fig">Fig. 8A</xref>), COPS6 (<xref rid="f8-ol-0-0-13064" ref-type="fig">Fig. 8B</xref>), COPS7A (<xref rid="SD1-ol-0-0-13064" ref-type="supplementary-material">Fig. S1D</xref>) and COPS7B (<xref rid="f1-ol-0-0-13064" ref-type="fig">Fig. 1E</xref>) were notably upregulated in both the cytoplasm and the nucleus in the HNSCC tissues compared with that in normal oral epithelial tissues. COPS9 was increased in the normal oral epithelial tissue compared with that in the tumor tissues of HNSCC (<xref rid="SD1-ol-0-0-13064" ref-type="supplementary-material">Fig. S1F</xref>). COPS1 and COPS8 were not detected.</p>
</sec>
<sec>
<title>Role of COPS subunits in the survival of the HNSCC cell lines</title>
<p>To evaluate the importance of the COPS subunits, Project Achilles with CERES dependence scores was used. When the score was &#x003E;-1, it indicated that the gene was not essential for cell survival. Otherwise, the gene was considered important for cell survival. As shown in <xref rid="f9-ol-0-0-13064" ref-type="fig">Fig. 9A</xref> and <xref rid="SD1-ol-0-0-13064" ref-type="supplementary-material">Table SVIII</xref> among all the HNSCC cell lines, COPS6 was important for cell survival. COPS1, COPS3, COPS4, COPS5 and COPS8 were critical for cell survival in most HNSCC cell lines. COPS2 was significantly essential for only 2 HNSCC cell lines. COPS7A, COPS7B and COPS9 were not important for HNSCC cell survival. These results suggested that COPS1, COPS3, COPS4, COPS5, COPS6 and COPS8 are essential for HNSCC cell survival.</p>
</sec>
<sec>
<title>COPS5 and COPS6 are essential for cell growth and invasion of HNSCC cells</title>
<p>Taken together, COPS5 and COPS6 were associated with the survival of the HNSCC cells and could be detected in tumor samples using IHC. To confirm the biological function of COPS5 and COPS6 in HNSCC, the CAL27 and SCC25 cell lines were transfected with a control siRNA, si-COPS5 and si-COPS6. Western blot analysis showed that the protein expression level of COPS5 (<xref rid="f9-ol-0-0-13064" ref-type="fig">Fig. 9B and D</xref>) and COPS6 (<xref rid="f9-ol-0-0-13064" ref-type="fig">Fig. 9C and E</xref>) was notably decreased by the siRNA. As shown in <xref rid="f9-ol-0-0-13064" ref-type="fig">Fig. 9F and G</xref>, the cell viabilities of the CAL27 and SCC25 cell lines were significantly decreased by both si-COPS5 and si-COPS6 at 24 and 48 h time points (P&#x003C;0.05). To detect the cell migration effect, the CAL27 and SCC25 cell lines were transfected with control siRNA, si-COPS5 or si-COPS6. The results from the wound healing assay suggested that si-COPS5 and si-COPS6 inhibited the migration of the CAL27 and SCC25 cells (<xref rid="f9-ol-0-0-13064" ref-type="fig">Fig. 9H and I</xref>). These results suggested that COPS5 and COPS6 could be essential for growth and migration of the HNSCC cell lines.</p>
</sec>
</sec>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>In the present study, ONCOMINE and TCGA databases were analyzed and it was found that the COPS subunits were upregulated in HNSCC samples compared with that in normal tissues, except for COPS9. Using subgroup analysis, based on TNM stage, high mRNA expression level of COPS5, COPS6, COPS7B, COPS8 and COPS9 was associated with progression of HNSCC. Prognosis analysis, using Kaplan-Meier plotter and TCGA-HNSC dataset suggested that mRNA expression level of COPS2, COPS5, COPS6, COPS7A, COPS7B, COPS8 and COPS9 could have prognostic significance. Survival analysis in the HNSCC cell lines suggested that COPS1, COPS3, COPS4, COPS5, COPS6 and COPS8 were necessary for tumor cell survival. COPS5 and COPS6 were also found to be essential for growth and migration of the HNSCC cell lines. Taken together, the COPS subunits may be potential diagnostic biomarkers in the future, and COPS5 and COPS6 could be important genes in the progression of HNSCC.</p>
<p>COP9 is a component of a large, multi-subunit nuclear protein complex (<xref rid="b39-ol-0-0-13064" ref-type="bibr">39</xref>). As COPS interacts and forms supercomplexes with cullin-RING ubiquitin-ligases, COPS could regulate the process of protein ubiquitination and maintain protein homeostasis (<xref rid="b39-ol-0-0-13064" ref-type="bibr">39</xref>). Increasing evidence have hypothesized that tumor cells have a large burden of unfolded proteins due to numerous mutations in protein-coding sequences, which leads to aberrant process of ubiquitination (<xref rid="b41-ol-0-0-13064" ref-type="bibr">41</xref>). Hence, abnormal expression of COPS subunits could contribute to the carcinogenesis and progression of cancer (<xref rid="b42-ol-0-0-13064" ref-type="bibr">42</xref>). The deregulated expression of several COPS subunits has been found in different types of tumor (<xref rid="b14-ol-0-0-13064" ref-type="bibr">14</xref>&#x2013;<xref rid="b17-ol-0-0-13064" ref-type="bibr">17</xref>). However, not all the COPS subunits were investigated in most of these studies, and it cannot be ruled out that the expression of the COPS holo complex was changed instead of a single subunit. To the best of our best knowledge, the present study is the first study to investigate the expression and prognostic values of the different COPS9 subunits in HNSCC.</p>
<p>Previous studies have reported that some COPS subunits are overexpressed in various types of cancer (<xref rid="b14-ol-0-0-13064" ref-type="bibr">14</xref>&#x2013;<xref rid="b17-ol-0-0-13064" ref-type="bibr">17</xref>). For example, COPS5 and COPS6 were highly expressed in myeloma, lung cancer, colon adenocarcinoma, breast cancer, glioblastoma and leukemia (<xref rid="b25-ol-0-0-13064" ref-type="bibr">25</xref>). In the present study, the conservative COPS (COPS1-COPS8) were significantly upregulated in HNSCC tissues compared with that in normal tissues from TCGA database. However, the COPS9 was not differentially expressed in both TCGA and Oncomine databases. Notably, high expression of COPS5 and COPS6 were associated with tumor size, nodal metastasis and distant metastasis. These results suggested that COPS5 and COPS6 may play an important role in the progression of carcinogenesis. In fact, COPS5 and COPS6 regulate diverse signaling pathways to promote the development of other types of cancer. COPS5 collaborated with the oncogene, Myc, to contribute to cell invasion in breast cancer cell lines (<xref rid="b43-ol-0-0-13064" ref-type="bibr">43</xref>). By promoting the degradation of p27, COPS5 regulated the cytoplasm transport of p27, which assisted with HER2-activated cell growth, CDK2 and transformation efficiently in ovarian cancer (<xref rid="b44-ol-0-0-13064" ref-type="bibr">44</xref>,<xref rid="b45-ol-0-0-13064" ref-type="bibr">45</xref>). In addition, overexpression of COPS5 lead to reduced MDM2 self-ubiquitination and nuclear export of p53, which caused a dysregulation of Mdm2-P53 axis (<xref rid="b46-ol-0-0-13064" ref-type="bibr">46</xref>&#x2013;<xref rid="b49-ol-0-0-13064" ref-type="bibr">49</xref>). Similarly, overexpression of COPS6 binds to MDM2, and prevents the process of its auto-ubiquitination and degradation, which leads to the accumulation of MDM2 and decrease of p53 in breast cancer (<xref rid="b49-ol-0-0-13064" ref-type="bibr">49</xref>). The results from GSEA analysis suggested that overexpression of COPS5 or COPS6 was associated with p53 signaling pathway in HNSCC, which is consistent with previous reports (<xref rid="b15-ol-0-0-13064" ref-type="bibr">15</xref>). Notably, following knockdown of COPS5 and COPS6 using siRNA, these genes were found to be essential for growth and migration of the HNSCC cell lines. These results suggested the critical roles played by COPS5 and COPS6 in HNSCC.</p>
<p>A recent study indicated that overexpression of COPS8 induced the progression of epithelial-mesenchymal transition in colorectal cancer cells, which lead to migration and invasion of the cancer cells (<xref rid="b50-ol-0-0-13064" ref-type="bibr">50</xref>). By promoting the expression of hypoxia response genes (solute carrier family 2 and HIF1) and key dormancy markers, COPS8 arrested cell proliferation and notably enhanced cell survival under serum deprivation, with hypoxia or the chemotherapy drug, 5-fluorouracil (<xref rid="b50-ol-0-0-13064" ref-type="bibr">50</xref>). Consistent with these results, in the present study, high mRNA expression level of COPS8 was found in HNSCC tissues, and was associated with distant metastasis of cancer and indicated poor prognosis of HNSCC. In addition, COPS8 was important for cell survival in most HNSCC cell lines. Mechanically, high expression of COPS8 was associated with apoptosis, DNA repair and hypoxia response. Notably, COPS8 was not detected in HNSCC tissue using an IHC assay. We hypothesized that the insensitive primary antibody caused the inaccurate detection.</p>
<p>With respect to the other COPS subunits, the high mRNA expression level of COPS1, COPS3 and COPS4 was found in HNSCC tissues, but was not associated with TMN stages or prognosis. However, high expression of COPS1 was associated with poor prognosis in patients with advanced esophageal squamous cell carcinoma (<xref rid="b36-ol-0-0-13064" ref-type="bibr">36</xref>). Notably, COPS1, COPS3 and COPS4 were all necessary for cancer cell survival. A previous study also found that knockdown of COPS3 expression with a specific shRNA in hepatocellular carcinoma cell lines significantly suppressed the cancer growth both <italic>in vitro</italic> and <italic>in vivo</italic> (<xref rid="b51-ol-0-0-13064" ref-type="bibr">51</xref>). COPS4 expression was essential for growth of breast cancer and prostate cancer cell lines (<xref rid="b52-ol-0-0-13064" ref-type="bibr">52</xref>,<xref rid="b53-ol-0-0-13064" ref-type="bibr">53</xref>). The results from the present study suggested that COPS2 was highly expressed in tumor tissues and upregulated COPS2 was associated with poor prognosis in patients with HNSCC. Zhao <italic>et al</italic> (<xref rid="b54-ol-0-0-13064" ref-type="bibr">54</xref>) found that DDA1 promoted the progression of colorectal cancer by activating the NF&#x03BA;B-COPS2-GSK3&#x03B2; pathway. COPS7A and COPS7B were highly expressed in the HNSCC samples; however, the prognostic significance was different. High mRNA expression level of COPS7A was associated with poor prognosis in patients with HNSCC, but the exact opposite was found with COPS7B.</p>
<p>There are some limitations to the present study. First and most important, the majority of the study is bioinformatic analysis, and a lack of clinical and functional experiments to support the results, which may restrict the conclusion. Second, a few results are marginally significant in this study (HR values are close to 1), which make the results not very convincing. Third, in <xref rid="f3-ol-0-0-13064" ref-type="fig">Fig. 3</xref>, TX, NX, and MX are included in the sub-analysis. These ambiguous clinical data may lead some results unstable. Therefore, additional clinical and experimental studies should be performed in the future to focus on the association between the COPS subunits and HNSCC.</p>
<p>In conclusion, COPS1-8 mRNA expression level was upregulated in HNSCC tissues compared with that in normal tissues. The expression level of COPS2, COPS5, COPS6, COPS7A, COPS7B, COPS8 and COPS9 might be associated with the prognosis of patients with HNSCC. Notably, COPS5 and COPS6 were critical for the progression of HNSCC.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material id="SD1-ol-0-0-13064" content-type="local-data">
<caption>
<title>Supporting Data</title>
</caption>
<media mimetype="application" mime-subtype="pdf" xlink:href="Supplementary_Data.pdf"/>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>The authors would like to thank Professor Liang Jiang (the Department of Oral and Maxillofacial Surgery, Tongji Hospital, Hubei, China) for providing the cell lines.</p>
</ack>
<sec>
<title>Funding</title>
<p>This research was supported by a grant from the Youth Science Support Project of the Central Hospital of Wuhan (grant no. 201807632).</p>
</sec>
<sec sec-type="data-availability">
<title>Availability of data and materials</title>
<p>All data generated or analyzed during this study are included in this published article.</p>
</sec>
<sec>
<title>Ethics approval and consent to participate</title>
<p>Not applicable.</p>
</sec>
<sec>
<title>Patient consent for publication</title>
<p>Not applicable.</p>
</sec>
<sec>
<title>Authors&#x0027; contributions</title>
<p>HZ designed the study and performed the bioinformatic analysis. JZ performed the western blot, CCK-8 and wound healing assays. WS analyzed the data. HZ and JZ wrote the manuscript. All authors approve the final version of the manuscript. HZ and JZ confirm the authenticity of all the raw data.</p>
</sec>
<sec sec-type="COI-statement">
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="b1-ol-0-0-13064"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forastiere</surname><given-names>AA</given-names></name><name><surname>Trotti</surname><given-names>A</given-names></name><name><surname>Pfister</surname><given-names>DG</given-names></name><name><surname>Grandis</surname><given-names>JR</given-names></name></person-group><article-title>Head and neck cancer: Recent advances and new standards of care</article-title><source>J Clin Oncol</source><volume>24</volume><fpage>2603</fpage><lpage>2605</lpage><year>2006</year><pub-id pub-id-type="doi">10.1200/JCO.2006.07.1464</pub-id><pub-id pub-id-type="pmid">16763271</pub-id></element-citation></ref>
<ref id="b2-ol-0-0-13064"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haddad</surname><given-names>RI</given-names></name><name><surname>Shin</surname><given-names>DM</given-names></name></person-group><article-title>Recent advances in head and neck cancer</article-title><source>N Engl J Med</source><volume>359</volume><fpage>1143</fpage><lpage>1154</lpage><year>2008</year><pub-id pub-id-type="doi">10.1056/NEJMra0707975</pub-id><pub-id pub-id-type="pmid">18784104</pub-id></element-citation></ref>
<ref id="b3-ol-0-0-13064"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lo Nigro</surname><given-names>C</given-names></name><name><surname>Denaro</surname><given-names>N</given-names></name><name><surname>Merlotti</surname><given-names>A</given-names></name><name><surname>Merlano</surname><given-names>M</given-names></name></person-group><article-title>Head and neck cancer: Improving outcomes with a multidisciplinary approach</article-title><source>Cancer Manag Res</source><volume>9</volume><fpage>363</fpage><lpage>371</lpage><year>2017</year><pub-id pub-id-type="doi">10.2147/CMAR.S115761</pub-id><pub-id pub-id-type="pmid">28860859</pub-id></element-citation></ref>
<ref id="b4-ol-0-0-13064"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khurshid</surname><given-names>Z</given-names></name><name><surname>Zafar</surname><given-names>MS</given-names></name><name><surname>Khan</surname><given-names>RS</given-names></name><name><surname>Najeeb</surname><given-names>S</given-names></name><name><surname>Slowey</surname><given-names>PD</given-names></name><name><surname>Rehman</surname><given-names>IU</given-names></name></person-group><article-title>Role of salivary biomarkers in oral cancer detection</article-title><source>Adv Clin Chem</source><volume>86</volume><fpage>23</fpage><lpage>70</lpage><year>2018</year><pub-id pub-id-type="doi">10.1016/bs.acc.2018.05.002</pub-id><pub-id pub-id-type="pmid">30144841</pub-id></element-citation></ref>
<ref id="b5-ol-0-0-13064"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahibzada</surname><given-names>HA</given-names></name><name><surname>Khurshid</surname><given-names>Z</given-names></name><name><surname>Khan</surname><given-names>RS</given-names></name><name><surname>Naseem</surname><given-names>M</given-names></name><name><surname>Siddique</surname><given-names>KM</given-names></name><name><surname>Mali</surname><given-names>M</given-names></name><name><surname>Zafar</surname><given-names>MS</given-names></name></person-group><article-title>Salivary IL-8, IL-6 and TNF-&#x03B1; as potential diagnostic biomarkers for oral cancer</article-title><source>Diagnostics (Basel)</source><volume>7</volume><fpage>21</fpage><year>2017</year><pub-id pub-id-type="doi">10.3390/diagnostics7020021</pub-id><pub-id pub-id-type="pmid">28397778</pub-id></element-citation></ref>
<ref id="b6-ol-0-0-13064"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubiel</surname><given-names>W</given-names></name><name><surname>Chaithongyot</surname><given-names>S</given-names></name><name><surname>Dubiel</surname><given-names>D</given-names></name><name><surname>Naumann</surname><given-names>M</given-names></name></person-group><article-title>The COP9 signalosome: A multi-DUB complex</article-title><source>Biomolecules</source><volume>10</volume><fpage>1082</fpage><year>2020</year><pub-id pub-id-type="doi">10.3390/biom10071082</pub-id><pub-id pub-id-type="pmid">32708147</pub-id></element-citation></ref>
<ref id="b7-ol-0-0-13064"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavadini</surname><given-names>S</given-names></name><name><surname>Fischer</surname><given-names>ES</given-names></name><name><surname>Bunker</surname><given-names>RD</given-names></name><name><surname>Potenza</surname><given-names>A</given-names></name><name><surname>Lingaraju</surname><given-names>GM</given-names></name><name><surname>Goldie</surname><given-names>KN</given-names></name><name><surname>Mohamed</surname><given-names>WI</given-names></name><name><surname>Faty</surname><given-names>M</given-names></name><name><surname>Petzold</surname><given-names>G</given-names></name><name><surname>Beckwith</surname><given-names>RE</given-names></name><etal/></person-group><article-title>Cullin-RING ubiquitin E3 ligase regulation by the COP9 signalosome</article-title><source>Nature</source><volume>531</volume><fpage>598</fpage><lpage>603</lpage><year>2016</year><pub-id pub-id-type="doi">10.1038/nature17416</pub-id><pub-id pub-id-type="pmid">27029275</pub-id></element-citation></ref>
<ref id="b8-ol-0-0-13064"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lingaraju</surname><given-names>GM</given-names></name><name><surname>Bunker</surname><given-names>RD</given-names></name><name><surname>Cavadini</surname><given-names>S</given-names></name><name><surname>Hess</surname><given-names>D</given-names></name><name><surname>Hassiepen</surname><given-names>U</given-names></name><name><surname>Renatus</surname><given-names>M</given-names></name><name><surname>Fischer</surname><given-names>ES</given-names></name><name><surname>Thom&#x00E4;</surname><given-names>NH</given-names></name></person-group><article-title>Crystal structure of the human COP9 signalosome</article-title><source>Nature</source><volume>512</volume><fpage>161</fpage><lpage>165</lpage><year>2014</year><pub-id pub-id-type="doi">10.1038/nature13566</pub-id><pub-id pub-id-type="pmid">25043011</pub-id></element-citation></ref>
<ref id="b9-ol-0-0-13064"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>N</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Deng</surname><given-names>XW</given-names></name></person-group><article-title>COP9 signalosome: Discovery, conservation, activity, and function</article-title><source>J Integr Plant Biol</source><volume>62</volume><fpage>90</fpage><lpage>103</lpage><year>2020</year><pub-id pub-id-type="doi">10.1111/jipb.12903</pub-id><pub-id pub-id-type="pmid">31894894</pub-id></element-citation></ref>
<ref id="b10-ol-0-0-13064"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>F</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name></person-group><article-title>Cullin-RING ligase regulation by the COP9 signalosome: Structural mechanisms and new physiologic players</article-title><source>Adv Exp Med Biol</source><volume>1217</volume><fpage>47</fpage><lpage>60</lpage><year>2020</year><pub-id pub-id-type="doi">10.1007/978-981-15-1025-0_4</pub-id><pub-id pub-id-type="pmid">31898221</pub-id></element-citation></ref>
<ref id="b11-ol-0-0-13064"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebina</surname><given-names>M</given-names></name><name><surname>Tsuruta</surname><given-names>F</given-names></name><name><surname>Katoh</surname><given-names>M</given-names></name><name><surname>Kigoshi</surname><given-names>Y</given-names></name><name><surname>Someya</surname><given-names>A</given-names></name><name><surname>Chiba</surname><given-names>T</given-names></name></person-group><article-title>Myeloma overexpressed 2 (Myeov2) regulates L11 subnuclear localization through Nedd8 modification</article-title><source>PLoS One</source><volume>8</volume><fpage>e65285</fpage><year>2013</year><pub-id pub-id-type="doi">10.1371/journal.pone.0065285</pub-id><pub-id pub-id-type="pmid">23776465</pub-id></element-citation></ref>
<ref id="b12-ol-0-0-13064"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Deng</surname><given-names>XW</given-names></name></person-group><article-title>The COP9 signalosome: An alternative lid for the 26S proteasome?</article-title><source>Trends Cell Biol</source><volume>13</volume><fpage>507</fpage><lpage>509</lpage><year>2003</year><pub-id pub-id-type="doi">10.1016/j.tcb.2003.08.002</pub-id><pub-id pub-id-type="pmid">14507477</pub-id></element-citation></ref>
<ref id="b13-ol-0-0-13064"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karniol</surname><given-names>B</given-names></name><name><surname>Chamovitz</surname><given-names>DA</given-names></name></person-group><article-title>The COP9 signalosome: From light signaling to general developmental regulation and back</article-title><source>Curr Opin Plant Biol</source><volume>3</volume><fpage>387</fpage><lpage>393</lpage><year>2000</year><pub-id pub-id-type="doi">10.1016/S1369-5266(00)00101-1</pub-id><pub-id pub-id-type="pmid">11019806</pub-id></element-citation></ref>
<ref id="b14-ol-0-0-13064"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomoda</surname><given-names>K</given-names></name><name><surname>Kubota</surname><given-names>Y</given-names></name><name><surname>Kato</surname><given-names>J</given-names></name></person-group><article-title>Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1</article-title><source>Nature</source><volume>398</volume><fpage>160</fpage><lpage>165</lpage><year>1999</year><pub-id pub-id-type="doi">10.1038/18230</pub-id><pub-id pub-id-type="pmid">10086358</pub-id></element-citation></ref>
<ref id="b15-ol-0-0-13064"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bech-Otschir</surname><given-names>D</given-names></name><name><surname>Kraft</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Henklein</surname><given-names>P</given-names></name><name><surname>Kapelari</surname><given-names>B</given-names></name><name><surname>Pollmann</surname><given-names>C</given-names></name><name><surname>Dubiel</surname><given-names>W</given-names></name></person-group><article-title>COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system</article-title><source>EMBO J</source><volume>20</volume><fpage>1630</fpage><lpage>1639</lpage><year>2001</year><pub-id pub-id-type="doi">10.1093/emboj/20.7.1630</pub-id><pub-id pub-id-type="pmid">11285227</pub-id></element-citation></ref>
<ref id="b16-ol-0-0-13064"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Choi</surname><given-names>JK</given-names></name><name><surname>Cinghu</surname><given-names>S</given-names></name><name><surname>Jang</surname><given-names>JW</given-names></name><name><surname>Lee</surname><given-names>YS</given-names></name><name><surname>Li</surname><given-names>YH</given-names></name><name><surname>Goh</surname><given-names>YM</given-names></name><name><surname>Chi</surname><given-names>XZ</given-names></name><name><surname>Lee</surname><given-names>KS</given-names></name><name><surname>Wee</surname><given-names>H</given-names></name><name><surname>Bae</surname><given-names>SC</given-names></name></person-group><article-title>Jab1/CSN5 induces the cytoplasmic localization and degradation of RUNX3</article-title><source>J Cell Biochem</source><volume>107</volume><fpage>557</fpage><lpage>565</lpage><year>2009</year><pub-id pub-id-type="doi">10.1002/jcb.22157</pub-id><pub-id pub-id-type="pmid">19350572</pub-id></element-citation></ref>
<ref id="b17-ol-0-0-13064"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bemis</surname><given-names>L</given-names></name><name><surname>Chan</surname><given-names>DA</given-names></name><name><surname>Finkielstein</surname><given-names>CV</given-names></name><name><surname>Qi</surname><given-names>L</given-names></name><name><surname>Sutphin</surname><given-names>PD</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Stenmark</surname><given-names>K</given-names></name><name><surname>Giaccia</surname><given-names>AJ</given-names></name><name><surname>Zundel</surname><given-names>W</given-names></name></person-group><article-title>Distinct aerobic and hypoxic mechanisms of HIF-alpha regulation by CSN5</article-title><source>Genes Dev</source><volume>18</volume><fpage>739</fpage><lpage>744</lpage><year>2004</year><pub-id pub-id-type="doi">10.1101/gad.1180104</pub-id><pub-id pub-id-type="pmid">15082527</pub-id></element-citation></ref>
<ref id="b18-ol-0-0-13064"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Fang</surname><given-names>J</given-names></name><name><surname>Du</surname><given-names>D</given-names></name><name><surname>Tian</surname><given-names>Z</given-names></name><name><surname>Zhen</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><etal/></person-group><article-title>CSN5 promotes carcinogenesis of thyroid carcinoma cells through ANGPTL2</article-title><source>Endocrinology</source><volume>162</volume><fpage>bqaa206</fpage><year>2021</year><pub-id pub-id-type="doi">10.1210/endocr/bqaa206</pub-id><pub-id pub-id-type="pmid">33508120</pub-id></element-citation></ref>
<ref id="b19-ol-0-0-13064"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>J</given-names></name><name><surname>Deng</surname><given-names>Q</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Zou</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Tan</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Cui</surname><given-names>H</given-names></name></person-group><article-title>CSN6 controls the proliferation and metastasis of glioblastoma by CHIP-mediated degradation of EGFR</article-title><source>Oncogene</source><volume>36</volume><fpage>1134</fpage><lpage>1144</lpage><year>2017</year><pub-id pub-id-type="doi">10.1038/onc.2016.280</pub-id><pub-id pub-id-type="pmid">27546621</pub-id></element-citation></ref>
<ref id="b20-ol-0-0-13064"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Lou</surname><given-names>L</given-names></name><name><surname>Nie</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Chang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name></person-group><article-title>EGFR-ERK pathway regulates CSN6 to contribute to PD-L1 expression in glioblastoma</article-title><source>Mol Carcinog</source><volume>59</volume><fpage>520</fpage><lpage>532</lpage><year>2020</year><pub-id pub-id-type="doi">10.1002/mc.23176</pub-id><pub-id pub-id-type="pmid">32134157</pub-id></element-citation></ref>
<ref id="b21-ol-0-0-13064"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubois</surname><given-names>EL</given-names></name><name><surname>Gerber</surname><given-names>S</given-names></name><name><surname>Kisselev</surname><given-names>A</given-names></name><name><surname>Harel-Bellan</surname><given-names>A</given-names></name><name><surname>Groisman</surname><given-names>R</given-names></name></person-group><article-title>UV-dependent phosphorylation of COP9/signalosome in UV-induced apoptosis</article-title><source>Oncol Rep</source><volume>35</volume><fpage>3101</fpage><lpage>3105</lpage><year>2016</year><pub-id pub-id-type="doi">10.3892/or.2016.4671</pub-id><pub-id pub-id-type="pmid">26986008</pub-id></element-citation></ref>
<ref id="b22-ol-0-0-13064"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoneda-Kato</surname><given-names>N</given-names></name><name><surname>Tomoda</surname><given-names>K</given-names></name><name><surname>Umehara</surname><given-names>M</given-names></name><name><surname>Arata</surname><given-names>Y</given-names></name><name><surname>Kato</surname><given-names>JY</given-names></name></person-group><article-title>Myeloid leukemia factor 1 regulates p53 by suppressing COP1 via COP9 signalosome subunit 3</article-title><source>EMBO J</source><volume>24</volume><fpage>1739</fpage><lpage>1749</lpage><year>2005</year><pub-id pub-id-type="doi">10.1038/sj.emboj.7600656</pub-id><pub-id pub-id-type="pmid">15861129</pub-id></element-citation></ref>
<ref id="b23-ol-0-0-13064"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pollmann</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Mall</surname><given-names>J</given-names></name><name><surname>Bech-Otschir</surname><given-names>D</given-names></name><name><surname>Naumann</surname><given-names>M</given-names></name><name><surname>Dubiel</surname><given-names>W</given-names></name></person-group><article-title>The constitutive photomorphogenesis 9 signalosome directs vascular endothelial growth factor production in tumor cells</article-title><source>Cancer Res</source><volume>61</volume><fpage>8416</fpage><lpage>8421</lpage><year>2001</year><pub-id pub-id-type="pmid">11731421</pub-id></element-citation></ref>
<ref id="b24-ol-0-0-13064"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denti</surname><given-names>S</given-names></name><name><surname>Fernandez-Sanchez</surname><given-names>ME</given-names></name><name><surname>Rogge</surname><given-names>L</given-names></name><name><surname>Bianchi</surname><given-names>E</given-names></name></person-group><article-title>The COP9 signalosome regulates Skp2 levels and proliferation of human cells</article-title><source>J Biol Chem</source><volume>281</volume><fpage>32188</fpage><lpage>32196</lpage><year>2006</year><pub-id pub-id-type="doi">10.1074/jbc.M604746200</pub-id><pub-id pub-id-type="pmid">16943200</pub-id></element-citation></ref>
<ref id="b25-ol-0-0-13064"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>MH</given-names></name><name><surname>Zhao</surname><given-names>R</given-names></name><name><surname>Phan</surname><given-names>L</given-names></name><name><surname>Yeung</surname><given-names>SC</given-names></name></person-group><article-title>Roles of COP9 signalosome in cancer</article-title><source>Cell Cycle</source><volume>10</volume><fpage>3057</fpage><lpage>3066</lpage><year>2011</year><pub-id pub-id-type="doi">10.4161/cc.10.18.17320</pub-id><pub-id pub-id-type="pmid">21876386</pub-id></element-citation></ref>
<ref id="b26-ol-0-0-13064"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Yan</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Lan</surname><given-names>B</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Identification of serum biomarkers for gastric cancer diagnosis using a human proteome microarray</article-title><source>Mol Cell Proteomics</source><volume>15</volume><fpage>614</fpage><lpage>623</lpage><year>2016</year><pub-id pub-id-type="doi">10.1074/mcp.M115.051250</pub-id><pub-id pub-id-type="pmid">26598640</pub-id></element-citation></ref>
<ref id="b27-ol-0-0-13064"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>T</given-names></name><name><surname>Wunder</surname><given-names>JS</given-names></name><name><surname>Gokgoz</surname><given-names>N</given-names></name><name><surname>Gill</surname><given-names>M</given-names></name><name><surname>Eskandarian</surname><given-names>S</given-names></name><name><surname>Parkes</surname><given-names>RK</given-names></name><name><surname>Bull</surname><given-names>SB</given-names></name><name><surname>Bell</surname><given-names>RS</given-names></name><name><surname>Andrulis</surname><given-names>IL</given-names></name></person-group><article-title>COPS3 amplification and clinical outcome in osteosarcoma</article-title><source>Cancer</source><volume>109</volume><fpage>1870</fpage><lpage>1876</lpage><year>2007</year><pub-id pub-id-type="doi">10.1002/cncr.22595</pub-id><pub-id pub-id-type="pmid">17366602</pub-id></element-citation></ref>
<ref id="b28-ol-0-0-13064"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>An</surname><given-names>L</given-names></name><name><surname>Ye</surname><given-names>H</given-names></name><name><surname>Ma</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name></person-group><article-title>Overexpression of COPS3 promotes clear cell renal cell carcinoma progression via regulation of Phospho-AKT(Thr308), cyclin D1 and caspase-3</article-title><source>Exp Cell Res</source><volume>365</volume><fpage>163</fpage><lpage>170</lpage><year>2018</year><pub-id pub-id-type="doi">10.1016/j.yexcr.2018.02.025</pub-id><pub-id pub-id-type="pmid">29477618</pub-id></element-citation></ref>
<ref id="b29-ol-0-0-13064"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>L</given-names></name></person-group><article-title>COPS8 in cutaneous melanoma: An oncogene that accelerates the malignant development of tumor cells and predicts poor prognosis</article-title><source>Biosci Biotechnol Biochem</source><volume>85</volume><fpage>242</fpage><lpage>250</lpage><year>2021</year><pub-id pub-id-type="doi">10.1093/bbb/zbaa017</pub-id><pub-id pub-id-type="pmid">33604618</pub-id></element-citation></ref>
<ref id="b30-ol-0-0-13064"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reis</surname><given-names>PP</given-names></name><name><surname>Waldron</surname><given-names>L</given-names></name><name><surname>Perez-Ordonez</surname><given-names>B</given-names></name><name><surname>Pintilie</surname><given-names>M</given-names></name><name><surname>Galloni</surname><given-names>NN</given-names></name><name><surname>Xuan</surname><given-names>Y</given-names></name><name><surname>Cervigne</surname><given-names>NK</given-names></name><name><surname>Warner</surname><given-names>GC</given-names></name><name><surname>Makitie</surname><given-names>AA</given-names></name><name><surname>Simpson</surname><given-names>C</given-names></name><etal/></person-group><article-title>A gene signature in histologically normal surgical margins is predictive of oral carcinoma recurrence</article-title><source>BMC Cancer</source><volume>11</volume><fpage>437</fpage><year>2011</year><pub-id pub-id-type="doi">10.1186/1471-2407-11-437</pub-id><pub-id pub-id-type="pmid">21989116</pub-id></element-citation></ref>
<ref id="b31-ol-0-0-13064"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dodd</surname><given-names>LE</given-names></name><name><surname>Sengupta</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>IH</given-names></name><name><surname>den Boon</surname><given-names>JA</given-names></name><name><surname>Cheng</surname><given-names>YJ</given-names></name><name><surname>Westra</surname><given-names>W</given-names></name><name><surname>Newton</surname><given-names>MA</given-names></name><name><surname>Mittl</surname><given-names>BF</given-names></name><name><surname>McShane</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>Genes involved in DNA repair and nitrosamine metabolism and those located on chromosome 14q32 are dysregulated in nasopharyngeal carcinoma</article-title><source>Cancer Epidemiol Biomarkers Prev</source><volume>15</volume><fpage>2216</fpage><lpage>2225</lpage><year>2006</year><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-06-0455</pub-id><pub-id pub-id-type="pmid">17119049</pub-id></element-citation></ref>
<ref id="b32-ol-0-0-13064"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlingemann</surname><given-names>J</given-names></name><name><surname>Habtemichael</surname><given-names>N</given-names></name><name><surname>Ittrich</surname><given-names>C</given-names></name><name><surname>Toedt</surname><given-names>G</given-names></name><name><surname>Kramer</surname><given-names>H</given-names></name><name><surname>Hambek</surname><given-names>M</given-names></name><name><surname>Knecht</surname><given-names>R</given-names></name><name><surname>Lichter</surname><given-names>P</given-names></name><name><surname>Stauber</surname><given-names>R</given-names></name><name><surname>Hahn</surname><given-names>M</given-names></name></person-group><article-title>Patient-based cross-platform comparison of oligonucleotide microarray expression profiles</article-title><source>Lab Invest</source><volume>85</volume><fpage>1024</fpage><lpage>1039</lpage><year>2005</year><pub-id pub-id-type="doi">10.1038/labinvest.3700293</pub-id><pub-id pub-id-type="pmid">16205657</pub-id></element-citation></ref>
<ref id="b33-ol-0-0-13064"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cromer</surname><given-names>A</given-names></name><name><surname>Carles</surname><given-names>A</given-names></name><name><surname>Millon</surname><given-names>R</given-names></name><name><surname>Ganguli</surname><given-names>G</given-names></name><name><surname>Chalmel</surname><given-names>F</given-names></name><name><surname>Lemaire</surname><given-names>F</given-names></name><name><surname>Young</surname><given-names>J</given-names></name><name><surname>Demb&#x00E9;l&#x00E9;</surname><given-names>D</given-names></name><name><surname>Thibault</surname><given-names>C</given-names></name><name><surname>Muller</surname><given-names>D</given-names></name><etal/></person-group><article-title>Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis</article-title><source>Oncogene</source><volume>23</volume><fpage>2484</fpage><lpage>2498</lpage><year>2004</year><pub-id pub-id-type="doi">10.1038/sj.onc.1207345</pub-id><pub-id pub-id-type="pmid">14676830</pub-id></element-citation></ref>
<ref id="b34-ol-0-0-13064"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toruner</surname><given-names>GA</given-names></name><name><surname>Ulger</surname><given-names>C</given-names></name><name><surname>Alkan</surname><given-names>M</given-names></name><name><surname>Galante</surname><given-names>AT</given-names></name><name><surname>Rinaggio</surname><given-names>J</given-names></name><name><surname>Wilk</surname><given-names>R</given-names></name><name><surname>Tian</surname><given-names>B</given-names></name><name><surname>Soteropoulos</surname><given-names>P</given-names></name><name><surname>Hameed</surname><given-names>MR</given-names></name><name><surname>Schwalb</surname><given-names>MN</given-names></name><name><surname>Dermody</surname><given-names>JJ</given-names></name></person-group><article-title>Association between gene expression profile and tumor invasion in oral squamous cell carcinoma</article-title><source>Cancer Genet Cytogenet</source><volume>154</volume><fpage>27</fpage><lpage>35</lpage><year>2004</year><pub-id pub-id-type="doi">10.1016/j.cancergencyto.2004.01.026</pub-id><pub-id pub-id-type="pmid">15381369</pub-id></element-citation></ref>
<ref id="b35-ol-0-0-13064"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginos</surname><given-names>MA</given-names></name><name><surname>Page</surname><given-names>GP</given-names></name><name><surname>Michalowicz</surname><given-names>BS</given-names></name><name><surname>Patel</surname><given-names>KJ</given-names></name><name><surname>Volker</surname><given-names>SE</given-names></name><name><surname>Pambuccian</surname><given-names>SE</given-names></name><name><surname>Ondrey</surname><given-names>FG</given-names></name><name><surname>Adams</surname><given-names>GL</given-names></name><name><surname>Gaffney</surname><given-names>PM</given-names></name></person-group><article-title>Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck</article-title><source>Cancer Res</source><volume>64</volume><fpage>55</fpage><lpage>63</lpage><year>2004</year><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-03-2144</pub-id><pub-id pub-id-type="pmid">14729608</pub-id></element-citation></ref>
<ref id="b36-ol-0-0-13064"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okuno</surname><given-names>T</given-names></name><name><surname>Wakabayashi</surname><given-names>M</given-names></name><name><surname>Kato</surname><given-names>K</given-names></name><name><surname>Shinoda</surname><given-names>M</given-names></name><name><surname>Katayama</surname><given-names>H</given-names></name><name><surname>Igaki</surname><given-names>H</given-names></name><name><surname>Tsubosa</surname><given-names>Y</given-names></name><name><surname>Kojima</surname><given-names>T</given-names></name><name><surname>Okabe</surname><given-names>H</given-names></name><name><surname>Kimura</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Esophageal stenosis and the Glasgow Prognostic Score as independent factors of poor prognosis for patients with locally advanced unresectable esophageal cancer treated with chemoradiotherapy (exploratory analysis of JCOG0303)</article-title><source>Int J Clin Oncol</source><volume>22</volume><fpage>1042</fpage><lpage>1049</lpage><year>2017</year><pub-id pub-id-type="doi">10.1007/s10147-017-1154-6</pub-id><pub-id pub-id-type="pmid">28717855</pub-id></element-citation></ref>
<ref id="b37-ol-0-0-13064"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsherniak</surname><given-names>A</given-names></name><name><surname>Vazquez</surname><given-names>F</given-names></name><name><surname>Montgomery</surname><given-names>PG</given-names></name><name><surname>Weir</surname><given-names>BA</given-names></name><name><surname>Kryukov</surname><given-names>G</given-names></name><name><surname>Cowley</surname><given-names>GS</given-names></name><name><surname>Gill</surname><given-names>S</given-names></name><name><surname>Harrington</surname><given-names>WF</given-names></name><name><surname>Pantel</surname><given-names>S</given-names></name><name><surname>Krill-Burger</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Defining a cancer dependency map</article-title><source>Cell</source><volume>170</volume><fpage>564</fpage><lpage>576.e16</lpage><year>2017</year><pub-id pub-id-type="doi">10.1016/j.cell.2017.06.010</pub-id><pub-id pub-id-type="pmid">28753430</pub-id></element-citation></ref>
<ref id="b38-ol-0-0-13064"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irizarry</surname><given-names>RA</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Speed</surname><given-names>TP</given-names></name></person-group><article-title>Gene set enrichment analysis made simple</article-title><source>Stat Methods Med Res</source><volume>18</volume><fpage>565</fpage><lpage>575</lpage><year>2009</year><pub-id pub-id-type="doi">10.1177/0962280209351908</pub-id><pub-id pub-id-type="pmid">20048385</pub-id></element-citation></ref>
<ref id="b39-ol-0-0-13064"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>DA</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Wee</surname><given-names>S</given-names></name></person-group><article-title>The COP9 signalosome: An assembly and maintenance platform for cullin ubiquitin ligases?</article-title><source>Nat Cell Biol</source><volume>5</volume><fpage>1029</fpage><lpage>1033</lpage><year>2003</year><pub-id pub-id-type="doi">10.1038/ncb1203-1029</pub-id><pub-id pub-id-type="pmid">14647295</pub-id></element-citation></ref>
<ref id="b40-ol-0-0-13064"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>F&#x00FC;zesi-Levi</surname><given-names>MG</given-names></name><name><surname>Fainer</surname><given-names>I</given-names></name><name><surname>Ivanov Enchev</surname><given-names>R</given-names></name><name><surname>Ben-Nissan</surname><given-names>G</given-names></name><name><surname>Levin</surname><given-names>Y</given-names></name><name><surname>Kupervaser</surname><given-names>M</given-names></name><name><surname>Friedlander</surname><given-names>G</given-names></name><name><surname>Salame</surname><given-names>TM</given-names></name><name><surname>Nevo</surname><given-names>R</given-names></name><name><surname>Peter</surname><given-names>M</given-names></name><name><surname>Sharon</surname><given-names>M</given-names></name></person-group><article-title>CSNAP, the smallest CSN subunit, modulates proteostasis through cullin-RING ubiquitin ligases</article-title><source>Cell Death Differ</source><volume>27</volume><fpage>984</fpage><lpage>998</lpage><year>2020</year><pub-id pub-id-type="doi">10.1038/s41418-019-0392-8</pub-id><pub-id pub-id-type="pmid">31367012</pub-id></element-citation></ref>
<ref id="b41-ol-0-0-13064"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuroha</surname><given-names>K</given-names></name><name><surname>Ando</surname><given-names>K</given-names></name><name><surname>Nakagawa</surname><given-names>R</given-names></name><name><surname>Inada</surname><given-names>T</given-names></name></person-group><article-title>The Upf factor complex interacts with aberrant products derived from mRNAs containing a premature termination codon and facilitates their proteasomal degradation</article-title><source>J Biol Chem</source><volume>288</volume><fpage>28630</fpage><lpage>28640</lpage><year>2013</year><pub-id pub-id-type="doi">10.1074/jbc.M113.460691</pub-id><pub-id pub-id-type="pmid">23928302</pub-id></element-citation></ref>
<ref id="b42-ol-0-0-13064"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>N</given-names></name><name><surname>Deng</surname><given-names>XW</given-names></name></person-group><article-title>The COP9 signalosome</article-title><source>Annu Rev Cell Dev Biol</source><volume>19</volume><fpage>261</fpage><lpage>286</lpage><year>2003</year><pub-id pub-id-type="doi">10.1146/annurev.cellbio.19.111301.112449</pub-id><pub-id pub-id-type="pmid">14570571</pub-id></element-citation></ref>
<ref id="b43-ol-0-0-13064"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adler</surname><given-names>AS</given-names></name><name><surname>Lin</surname><given-names>M</given-names></name><name><surname>Horlings</surname><given-names>H</given-names></name><name><surname>Nuyten</surname><given-names>DS</given-names></name><name><surname>van de Vijver</surname><given-names>MJ</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name></person-group><article-title>Genetic regulators of large-scale transcriptional signatures in cancer</article-title><source>Nat Genet</source><volume>38</volume><fpage>421</fpage><lpage>430</lpage><year>2006</year><pub-id pub-id-type="doi">10.1038/ng1752</pub-id><pub-id pub-id-type="pmid">16518402</pub-id></element-citation></ref>
<ref id="b44-ol-0-0-13064"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sui</surname><given-names>L</given-names></name><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Ohno</surname><given-names>M</given-names></name><name><surname>Watanabe</surname><given-names>Y</given-names></name><name><surname>Sugimoto</surname><given-names>K</given-names></name><name><surname>Tai</surname><given-names>Y</given-names></name><name><surname>Tokuda</surname><given-names>M</given-names></name></person-group><article-title>Jab1 expression is associated with inverse expression of p27(kip1) and poor prognosis in epithelial ovarian tumors</article-title><source>Clin Cancer Res</source><volume>7</volume><fpage>4130</fpage><lpage>4135</lpage><year>2001</year><pub-id pub-id-type="pmid">11751512</pub-id></element-citation></ref>
<ref id="b45-ol-0-0-13064"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sutterl&#x00FC;ty</surname><given-names>H</given-names></name><name><surname>Chatelain</surname><given-names>E</given-names></name><name><surname>Marti</surname><given-names>A</given-names></name><name><surname>Wirbelauer</surname><given-names>C</given-names></name><name><surname>Senften</surname><given-names>M</given-names></name><name><surname>M&#x00FC;ller</surname><given-names>U</given-names></name><name><surname>Krek</surname><given-names>W</given-names></name></person-group><article-title>p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells</article-title><source>Nat Cell Biol</source><volume>1</volume><fpage>207</fpage><lpage>214</lpage><year>1999</year><pub-id pub-id-type="doi">10.1038/12027</pub-id><pub-id pub-id-type="pmid">10559918</pub-id></element-citation></ref>
<ref id="b46-ol-0-0-13064"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>BP</given-names></name><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>W</given-names></name><name><surname>Zou</surname><given-names>Y</given-names></name><name><surname>Spohn</surname><given-names>B</given-names></name><name><surname>Hung</surname><given-names>MC</given-names></name></person-group><article-title>HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation</article-title><source>Nat Cell Biol</source><volume>3</volume><fpage>973</fpage><lpage>982</lpage><year>2001</year><pub-id pub-id-type="doi">10.1038/ncb1101-973</pub-id><pub-id pub-id-type="pmid">11715018</pub-id></element-citation></ref>
<ref id="b47-ol-0-0-13064"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernardi</surname><given-names>R</given-names></name><name><surname>Scaglioni</surname><given-names>PP</given-names></name><name><surname>Bergmann</surname><given-names>S</given-names></name><name><surname>Horn</surname><given-names>HF</given-names></name><name><surname>Vousden</surname><given-names>KH</given-names></name><name><surname>Pandolfi</surname><given-names>PP</given-names></name></person-group><article-title>PML regulates p53 stability by sequestering Mdm2 to the nucleolus</article-title><source>Nat Cell Biol</source><volume>6</volume><fpage>665</fpage><lpage>672</lpage><year>2004</year><pub-id pub-id-type="doi">10.1038/ncb1147</pub-id><pub-id pub-id-type="pmid">15195100</pub-id></element-citation></ref>
<ref id="b48-ol-0-0-13064"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>W</given-names></name><name><surname>Lee</surname><given-names>EW</given-names></name><name><surname>Sung</surname><given-names>YH</given-names></name><name><surname>Yang</surname><given-names>MR</given-names></name><name><surname>Ghim</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>HW</given-names></name><name><surname>Song</surname><given-names>J</given-names></name></person-group><article-title>Jab1 induces the cytoplasmic localization and degradation of p53 in coordination with Hdm2</article-title><source>J Biol Chem</source><volume>281</volume><fpage>17457</fpage><lpage>17465</lpage><year>2006</year><pub-id pub-id-type="doi">10.1074/jbc.M601857200</pub-id><pub-id pub-id-type="pmid">16624822</pub-id></element-citation></ref>
<ref id="b49-ol-0-0-13064"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>R</given-names></name><name><surname>Yeung</surname><given-names>SC</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Iwakuma</surname><given-names>T</given-names></name><name><surname>Su</surname><given-names>CH</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name><name><surname>Qu</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>YT</given-names></name><name><surname>Lin</surname><given-names>YL</given-names></name><etal/></person-group><article-title>Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers</article-title><source>J Clin Invest</source><volume>121</volume><fpage>851</fpage><lpage>865</lpage><year>2011</year><pub-id pub-id-type="doi">10.1172/JCI44111</pub-id><pub-id pub-id-type="pmid">21317535</pub-id></element-citation></ref>
<ref id="b50-ol-0-0-13064"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ju</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Ju</surname><given-names>S</given-names></name></person-group><article-title>CSN8 is a key regulator in hypoxia-induced epithelial-mesenchymal transition and dormancy of colorectal cancer cells</article-title><source>Mol Cancer</source><volume>19</volume><fpage>168</fpage><year>2020</year><pub-id pub-id-type="doi">10.1186/s12943-020-01285-4</pub-id><pub-id pub-id-type="pmid">33261601</pub-id></element-citation></ref>
<ref id="b51-ol-0-0-13064"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>YS</given-names></name><name><surname>Tang</surname><given-names>ZH</given-names></name><name><surname>Pan</surname><given-names>QC</given-names></name><name><surname>Chen</surname><given-names>XH</given-names></name><name><surname>Liu</surname><given-names>XN</given-names></name><name><surname>Zang</surname><given-names>GQ</given-names></name></person-group><article-title>Inhibition of Csn3 expression induces growth arrest and apoptosis of hepatocellular carcinoma cells</article-title><source>Cancer Chemother Pharmacol</source><volume>69</volume><fpage>1173</fpage><lpage>1180</lpage><year>2012</year><pub-id pub-id-type="doi">10.1007/s00280-011-1810-x</pub-id><pub-id pub-id-type="pmid">22237956</pub-id></element-citation></ref>
<ref id="b52-ol-0-0-13064"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhansali</surname><given-names>M</given-names></name><name><surname>Shemshedini</surname><given-names>L</given-names></name></person-group><article-title>COP9 subunits 4 and 5 target soluble guanylyl cyclase &#x03B1;1 and p53 in prostate cancer cells</article-title><source>Mol Endocrinol</source><volume>28</volume><fpage>834</fpage><lpage>845</lpage><year>2014</year><pub-id pub-id-type="doi">10.1210/me.2014-1017</pub-id><pub-id pub-id-type="pmid">24725084</pub-id></element-citation></ref>
<ref id="b53-ol-0-0-13064"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>TL</given-names></name><name><surname>Cai</surname><given-names>DL</given-names></name><name><surname>Zhu</surname><given-names>GF</given-names></name><name><surname>Ye</surname><given-names>XJ</given-names></name><name><surname>Min</surname><given-names>TS</given-names></name><name><surname>Chen</surname><given-names>HY</given-names></name><name><surname>Lu</surname><given-names>DR</given-names></name><name><surname>Chen</surname><given-names>HM</given-names></name></person-group><article-title>Effects of CSN4 knockdown on proliferation and apoptosis of breast cancer MDA-MB-231 cells</article-title><source>Yi Chuan</source><volume>41</volume><fpage>318</fpage><lpage>326</lpage><year>2019</year><comment>(In Chinese)</comment><pub-id pub-id-type="pmid">30992253</pub-id></element-citation></ref>
<ref id="b54-ol-0-0-13064"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Yan</surname><given-names>D</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Wen</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>F</given-names></name><name><surname>Cui</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Xue</surname><given-names>Y</given-names></name><etal/></person-group><article-title>DDA1 promotes stage IIB-IIC colon cancer progression by activating NF&#x03BA;B/CSN2/GSK-3&#x03B2; signaling</article-title><source>Oncotarget</source><volume>7</volume><fpage>19794</fpage><lpage>19812</lpage><year>2016</year><pub-id pub-id-type="doi">10.18632/oncotarget.7847</pub-id><pub-id pub-id-type="pmid">26942699</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-ol-0-0-13064" position="float">
<label>Figure 1.</label>
<caption><p>Expression level of the COPS subunits was increased in the HNSCC samples. The mRNA expression profiles of (A) COPS1, (B) COPSS2, (C) COPS3, (D) COPS4, (E) COPS5, (F) COPS6, (G) COPS7A, (H) COPS7B, (I) COPS8 and (J) COPS9 in HNSCC and normal tissue samples were obtained from the UALCAN database. &#x002A;P&#x003C;0.05. &#x002A;&#x002A;P&#x003C;0.01. &#x002A;&#x002A;&#x002A;P&#x003C;0.001. COPS, COP9 signalosome; HNSCC, head and neck squamous cell carcinoma.</p></caption>
<graphic xlink:href="ol-22-05-13064-g00.tiff"/>
</fig>
<fig id="f2-ol-0-0-13064" position="float">
<label>Figure 2.</label>
<caption><p>mRNA transcriptional levels of the COPS subunits in diverse types of cancer. The mRNA transcriptional levels of COPS in different types of cancer from the Oncomine database. The numbers in the box indicate statistically significant overexpression (red) or downregulation (blue) of the COPS subunits in cancer tissues compared with that in normal tissues. COPS, COP9 Signalosome.</p></caption>
<graphic xlink:href="ol-22-05-13064-g01.tiff"/>
</fig>
<fig id="f3-ol-0-0-13064" position="float">
<label>Figure 3.</label>
<caption><p>Analysis of COPS subunits and clinical characteristics. Subgroup analysis of the COPS subunits based on (A) tumor size, (B) nodal metastasis and (C) distant metastasis in head and neck squamous cell carcinoma samples was evaluated using the UCSC Xena database. &#x002A;P&#x003C;0.05. &#x002A;&#x002A;P&#x003C;0.01. &#x002A;&#x002A;&#x002A;P&#x003C;0.001. COPS, COP9 signalosome.</p></caption>
<graphic xlink:href="ol-22-05-13064-g02.tiff"/>
</fig>
<fig id="f4-ol-0-0-13064" position="float">
<label>Figure 4.</label>
<caption><p>COPS subunit expression and prognostic value in patients with HNSCC. The prognostic value of (A) COPS1, (B) COPS2, (C) COPS3, (D) COPS4, (E) COPS5, (F) COPS6, (G) COPS7A, (H) COPS7B, (I) COPS8 and (J) COPS9 in the head and neck squamous cell carcinoma tissues was determined using the Kaplan-Meier plotter database and the mRNA expression profiles. COPS, COP9 signalosome; HR, hazard ratio.</p></caption>
<graphic xlink:href="ol-22-05-13064-g03.tiff"/>
</fig>
<fig id="f5-ol-0-0-13064" position="float">
<label>Figure 5.</label>
<caption><p>PPI network of the COPS subunits. The PPI network of the COPS subunits was constructed using STRING with the 50 most frequently altered neighbor genes and includes 60 nodes and 956 edges. COPS, COP9 signalosome; PPI, protein-protein interaction.</p></caption>
<graphic xlink:href="ol-22-05-13064-g04.tiff"/>
</fig>
<fig id="f6-ol-0-0-13064" position="float">
<label>Figure 6.</label>
<caption><p>Gene Ontology functional enrichment analysis of the COPS subunits. The bubble diagrams display the enrichment results of the COPS subunits and the top 50 genes altered in the COPS subunits in head and neck squamous cell carcinoma using Database for Annotation, Visualization and Integrated Discovery. (A) Biological processes. (B) Cellular components. (C) Molecular functions. (D) KEGG pathways. COPS, COP9 signalosome.</p></caption>
<graphic xlink:href="ol-22-05-13064-g05.tiff"/>
</fig>
<fig id="f7-ol-0-0-13064" position="float">
<label>Figure 7.</label>
<caption><p>GSEA of the COPS subunits in head and neck squamous cell carcinoma. GSEA analysis was performed with Hallmark annotation based on expression level of (A) COPS6, (B) COPS6 and (C) COPS8. The most (top 9) affected signal pathways are shown. COPS, COP9 signalosome; GSEA, Gene Set Enrichment Analysis.</p></caption>
<graphic xlink:href="ol-22-05-13064-g06.tiff"/>
</fig>
<fig id="f8-ol-0-0-13064" position="float">
<label>Figure 8.</label>
<caption><p>Protein expression of the COPS subunits in HNSCC. Immunohistochemical staining images from the Human Protein Atlas portal was used to analyze protein expression of (A) COPS5 and (B) COPS6 in normal oral tissues and HNSCC. COPS, COP9 signalosome.</p></caption>
<graphic xlink:href="ol-22-05-13064-g07.tiff"/>
</fig>
<fig id="f9-ol-0-0-13064" position="float">
<label>Figure 9.</label>
<caption><p>COPS5 and COPS6 are important for cell growth and migration in HNSCC cells. (A) CERES score was downloaded from Depmap and used to evaluate the significance of the COPS subunits for survival of the HNSCC cell lines. The CAL27 (B and C) and SCC25 (D and E) cell lines were transfected with control siRNA, si-COPS5 or si-COPS6 for 48 h, then western blot analysis was used to detect the protein expression of COPS5 or COPS6. A Cell Counting Kit-8 assay was performed to detect cell viability of the (F) CAL27 and (G) SCC25 cell lines following transfection with siRNA. (H) A wound healing assay was performed to determine the cell migration of the CAL27 and SCC25 cells following transfection with siRNA and the results were (I) quantified. &#x002A;P&#x003C;0.05, &#x002A;&#x002A;P&#x003C;0.01 and &#x002A;&#x002A;&#x002A;P&#x003C;0.001. COPS, COP9 signalosome; HNSCC, head and neck squamous cell carcinoma.</p></caption>
<graphic xlink:href="ol-22-05-13064-g08.tiff"/>
</fig>
<table-wrap id="tI-ol-0-0-13064" position="float">
<label>Table I.</label>
<caption><p>Expression of the COPS families in head and neck squamous cell carcinoma.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="bottom">Gene name</th>
<th align="center" valign="bottom">Cancer type (n)</th>
<th align="center" valign="bottom">P-value</th>
<th align="center" valign="bottom">Fold change</th>
<th align="center" valign="bottom">T-test</th>
<th align="center" valign="bottom">(Refs.)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">COPS1</td>
<td align="left" valign="top">Floor of the mouth carcinoma (<xref rid="b5-ol-0-0-13064" ref-type="bibr">5</xref>)</td>
<td align="center" valign="top">4.00&#x00D7;10<sup>&#x2212;3</sup></td>
<td align="center" valign="top">1.543</td>
<td align="center" valign="top">3.837</td>
<td align="left" valign="top">Pyeon Multi-cancer (<xref rid="b50-ol-0-0-13064" ref-type="bibr">50</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">COPS2</td>
<td align="left" valign="top">Nasopharyngeal carcinoma (<xref rid="b31-ol-0-0-13064" ref-type="bibr">31</xref>)</td>
<td align="center" valign="top">2.80&#x00D7;10<sup>&#x2212;6</sup></td>
<td align="center" valign="top">2.095</td>
<td align="center" valign="top">5.746</td>
<td align="left" valign="top">Sengupta Head-Neck (<xref rid="b36-ol-0-0-13064" ref-type="bibr">36</xref>)</td>
</tr>
<tr>
<td/>
<td align="left" valign="top">Floor of the mouth carcinoma (<xref rid="b5-ol-0-0-13064" ref-type="bibr">5</xref>)</td>
<td align="center" valign="top">2.07&#x00D7;10<sup>&#x2212;4</sup></td>
<td align="center" valign="top">2.261</td>
<td align="center" valign="top">5.383</td>
<td align="left" valign="top">Pyeon Multi-cancer (<xref rid="b50-ol-0-0-13064" ref-type="bibr">50</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">COPS3</td>
<td align="left" valign="top">Oropharyngeal carcinoma (<xref rid="b6-ol-0-0-13064" ref-type="bibr">6</xref>)</td>
<td align="center" valign="top">3.32 &#x00D7;10<sup>&#x2212;4</sup></td>
<td align="center" valign="top">2.295</td>
<td align="center" valign="top">4.225</td>
<td align="left" valign="top">Pyeon Multi-cancer (<xref rid="b50-ol-0-0-13064" ref-type="bibr">50</xref>)</td>
</tr>
<tr>
<td/>
<td align="left" valign="top">Oral cavity carcinoma (<xref rid="b4-ol-0-0-13064" ref-type="bibr">4</xref>)</td>
<td align="center" valign="top">3.00&#x00D7;10<sup>&#x2212;3</sup></td>
<td align="center" valign="top">2.206</td>
<td align="center" valign="top">3.717</td>
<td align="left" valign="top">Pyeon Multi-cancer (<xref rid="b50-ol-0-0-13064" ref-type="bibr">50</xref>)</td>
</tr>
<tr>
<td/>
<td align="left" valign="top">Floor of the mouth carcinoma (<xref rid="b5-ol-0-0-13064" ref-type="bibr">5</xref>)</td>
<td align="center" valign="top">2.43&#x00D7;10<sup>&#x2212;4</sup></td>
<td align="center" valign="top">2.636</td>
<td align="center" valign="top">4.748</td>
<td align="left" valign="top">Pyeon Multi-cancer (<xref rid="b50-ol-0-0-13064" ref-type="bibr">50</xref>)</td>
</tr>
<tr>
<td/>
<td align="left" valign="top">Tongue carcinoma (<xref rid="b15-ol-0-0-13064" ref-type="bibr">15</xref>)</td>
<td align="center" valign="top">2.01&#x00D7;10<sup>&#x2212;4</sup></td>
<td align="center" valign="top">2.040</td>
<td align="center" valign="top">3.913</td>
<td align="left" valign="top">Pyeon Multi-cancer (<xref rid="b50-ol-0-0-13064" ref-type="bibr">50</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">COPS5</td>
<td align="left" valign="top">Tongue carcinoma (<xref rid="b15-ol-0-0-13064" ref-type="bibr">15</xref>)</td>
<td align="center" valign="top">3.88&#x00D7;10<sup>&#x2212;4</sup></td>
<td align="center" valign="top">2.755</td>
<td align="center" valign="top">6.009</td>
<td align="left" valign="top">Pyeon Multi-cancer (<xref rid="b50-ol-0-0-13064" ref-type="bibr">50</xref>)</td>
</tr>
<tr>
<td/>
<td align="left" valign="top">Floor of the mouth carcinoma (<xref rid="b5-ol-0-0-13064" ref-type="bibr">5</xref>)</td>
<td align="center" valign="top">1.71&#x00D7;10<sup>&#x2212;6</sup></td>
<td align="center" valign="top">4.533</td>
<td align="center" valign="top">8.121</td>
<td align="left" valign="top">Pyeon Multi-cancer (<xref rid="b50-ol-0-0-13064" ref-type="bibr">50</xref>)</td>
</tr>
<tr>
<td/>
<td align="left" valign="top">Oral cavity carcinoma (<xref rid="b4-ol-0-0-13064" ref-type="bibr">4</xref>)</td>
<td align="center" valign="top">2.26 &#x00D7;10<sup>&#x2212;4</sup></td>
<td align="center" valign="top">2.401</td>
<td align="center" valign="top">4.971</td>
<td align="left" valign="top">Pyeon Multi-cancer (<xref rid="b50-ol-0-0-13064" ref-type="bibr">50</xref>)</td>
</tr>
<tr>
<td/>
<td align="left" valign="top">Tonsillar carcinoma (<xref rid="b6-ol-0-0-13064" ref-type="bibr">6</xref>)</td>
<td align="center" valign="top">9.52&#x00D7;10<sup>&#x2212;4</sup></td>
<td align="center" valign="top">1.719</td>
<td align="center" valign="top">3.509</td>
<td align="left" valign="top">Pyeon Multi-cancer (<xref rid="b50-ol-0-0-13064" ref-type="bibr">50</xref>)</td>
</tr>
<tr>
<td/>
<td align="left" valign="top">Oropharyngeal carcinoma (<xref rid="b6-ol-0-0-13064" ref-type="bibr">6</xref>)</td>
<td align="center" valign="top">1.99&#x00D7;10<sup>&#x2212;4</sup></td>
<td align="center" valign="top">2.762</td>
<td align="center" valign="top">4.910</td>
<td align="left" valign="top">Pyeon Multi-cancer (<xref rid="b50-ol-0-0-13064" ref-type="bibr">50</xref>)</td>
</tr>
<tr>
<td/>
<td align="left" valign="top">Oral cavity squamous cell carcinoma (<xref rid="b16-ol-0-0-13064" ref-type="bibr">16</xref>)</td>
<td align="center" valign="top">3.88&#x00D7;10<sup>&#x2212;4</sup></td>
<td align="center" valign="top">1.823</td>
<td align="center" valign="top">4.826</td>
<td align="left" valign="top">Toruner Head-Neck Statistics (<xref rid="b53-ol-0-0-13064" ref-type="bibr">53</xref>)</td>
</tr>
<tr>
<td/>
<td align="left" valign="top">Nasopharyngeal carcinoma (<xref rid="b31-ol-0-0-13064" ref-type="bibr">31</xref>)</td>
<td align="center" valign="top">1.17&#x00D7;10<sup>&#x2212;4</sup></td>
<td align="center" valign="top">1.595</td>
<td align="center" valign="top">4.233</td>
<td align="left" valign="top">Sengupta Head-Neck Statistics (<xref rid="b36-ol-0-0-13064" ref-type="bibr">36</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">COPS6</td>
<td align="left" valign="top">Tonsillar carcinoma (<xref rid="b6-ol-0-0-13064" ref-type="bibr">6</xref>)</td>
<td align="center" valign="top">3.01&#x00D7;10<sup>&#x2212;4</sup></td>
<td align="center" valign="top">1.924</td>
<td align="center" valign="top">3.915</td>
<td align="left" valign="top">Pyeon Multi-cancer (<xref rid="b50-ol-0-0-13064" ref-type="bibr">50</xref>)</td>
</tr>
<tr>
<td/>
<td align="left" valign="top">Oral cavity carcinoma (<xref rid="b4-ol-0-0-13064" ref-type="bibr">4</xref>)</td>
<td align="center" valign="top">2.00&#x00D7;10<sup>&#x2212;3</sup></td>
<td align="center" valign="top">2.634</td>
<td align="center" valign="top">3.902</td>
<td align="left" valign="top">Pyeon Multi-cancer (<xref rid="b50-ol-0-0-13064" ref-type="bibr">50</xref>)</td>
</tr>
<tr>
<td/>
<td align="left" valign="top">Oropharyngeal carcinoma (<xref rid="b6-ol-0-0-13064" ref-type="bibr">6</xref>)</td>
<td align="center" valign="top">4.81&#x00D7;10<sup>&#x2212;4</sup></td>
<td align="center" valign="top">2.118</td>
<td align="center" valign="top">3.820</td>
<td align="left" valign="top">Pyeon Multi-cancer (<xref rid="b50-ol-0-0-13064" ref-type="bibr">50</xref>)</td>
</tr>
<tr>
<td/>
<td align="left" valign="top">Floor of the mouth carcinoma (<xref rid="b5-ol-0-0-13064" ref-type="bibr">5</xref>)</td>
<td align="center" valign="top">1.49&#x00D7;10<sup>&#x2212;4</sup></td>
<td align="center" valign="top">2.665</td>
<td align="center" valign="top">4.656</td>
<td align="left" valign="top">Pyeon Multi-cancer (<xref rid="b50-ol-0-0-13064" ref-type="bibr">50</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">COPS8</td>
<td align="left" valign="top">Hypopharyngeal squamous cell carcinoma (<xref rid="b4-ol-0-0-13064" ref-type="bibr">4</xref>)</td>
<td align="center" valign="top">5.00&#x00D7;10<sup>&#x2212;3</sup></td>
<td align="center" valign="top">2.533</td>
<td align="center" valign="top">3.794</td>
<td align="left" valign="top">Schlingemann Head-Neck (<xref rid="b52-ol-0-0-13064" ref-type="bibr">52</xref>)</td>
</tr>
<tr>
<td/>
<td align="left" valign="top">Head and neck squamous cell carcinoma (<xref rid="b34-ol-0-0-13064" ref-type="bibr">34</xref>)</td>
<td align="center" valign="top">6.70&#x00D7;10<sup>&#x2212;4</sup></td>
<td align="center" valign="top">2.001</td>
<td align="center" valign="top">5.820</td>
<td align="left" valign="top">Cromer Head-Neck (<xref rid="b52-ol-0-0-13064" ref-type="bibr">52</xref>)</td>
</tr>
<tr>
<td/>
<td align="left" valign="top">Head and neck squamous cell carcinoma (<xref rid="b41-ol-0-0-13064" ref-type="bibr">41</xref>)</td>
<td align="center" valign="top">3.48&#x00D7;10<sup>&#x2212;9</sup></td>
<td align="center" valign="top">1.617</td>
<td align="center" valign="top">7.125</td>
<td align="left" valign="top">Ginos Head-Neck (<xref rid="b54-ol-0-0-13064" ref-type="bibr">54</xref>)</td>
</tr>
<tr>
<td/>
<td align="left" valign="top">Oropharyngeal carcinoma (<xref rid="b6-ol-0-0-13064" ref-type="bibr">6</xref>)</td>
<td align="center" valign="top">1.21&#x00D7;10<sup>&#x2212;4</sup></td>
<td align="center" valign="top">2.021</td>
<td align="center" valign="top">4.791</td>
<td align="left" valign="top">Pyeon Multi-cancer (<xref rid="b50-ol-0-0-13064" ref-type="bibr">50</xref>)</td>
</tr>
<tr>
<td/>
<td align="left" valign="top">Nasopharyngeal carcinoma (<xref rid="b31-ol-0-0-13064" ref-type="bibr">31</xref>)</td>
<td align="center" valign="top">2.47&#x00D7;10<sup>&#x2212;4</sup></td>
<td align="center" valign="top">1.523</td>
<td align="center" valign="top">3.957</td>
<td align="left" valign="top">Sengupta Head-Neck (<xref rid="b36-ol-0-0-13064" ref-type="bibr">36</xref>)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tfn1-ol-0-0-13064"><p>COPS, COP9 signalosome.</p></fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
